≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Benign neoplasm: Spinal meninges

DOID EFO Endpoint Browser PheWeb

CD2_BENIGN_MENINGES_SPINAL

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D32.1&
  • Hospital discharge: ICD-9 — 2254
  • Hospital discharge: ICD-8 — 2254
  • Cause of death: ICD-10 — D32.1&
  • Cause of death: ICD-9 — 2254
  • Cause of death: ICD-8 — 2254

2 out of 7 registries used, show all original rules.

395

4. Check minimum number of events

None

395

5. Include endpoints

None

395

6. Filter based on genotype QC (FinnGen only)

383

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D32
Name in latin
Neoplasma benignum meningum spinalium

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2153 1510 634
Only index persons 1841 1306 535
Unadjusted period prevalence (%)
Whole population 0.04 0.04 0.02
Only index persons 0.04 0.05 0.02
Median age at first event (years)
Whole population 62.54 63.92 59.41
Only index persons 61.91 63.16 58.86

-FinnGen-

Key figures

All Female Male
Number of individuals 383 280 103
Unadjusted period prevalence (%) 0.09 0.10 0.05
Median age at first event (years) 62.99 62.93 63.13

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
395
Matched controls
3950
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D32.1
ICD-10 Finland
Benign neoplasm: Spinal meninges
+∞
307.7
370
*
ABB00
NOMESCO Finland
Excision of lesion of spinal canal
+∞
225.3
194
*
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
65.5
169.1
95
19
9530/0-C70.1
ICD-O-3
Meningioma, NOS, of spinal meninges
+∞
90.1
83
*
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
32.1
79.7
53
19
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
29.6
79.1
54
21
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
17.3
57.2
49
32
D32.01
ICD-10 Finland
Benign tumor of meninges on interhemispheric surface
78.2
53.9
60
9
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
11.7
50.4
55
54
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.5
50.4
98
192
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
15.9
39.6
35
24
9530/0-C70.9
ICD-O-3
Meningioma, NOS, of meninges, NOS
209.6
37.5
38
*
D33.45
ICD-10 Finland
Benign Schwannom in the nerve root of the spinal cord
135.7
35.3
37
*
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
6.4
33.5
61
110
D32.9
ICD-10 Finland
Benign neoplasm: Meninges, unspecified
78.8
32.5
36
5
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.9
31.8
119
389
9530/0-C70.0
ICD-O-3
Meningioma, NOS, of cerebral meninges
27.8
28.1
38
15
ABB10
NOMESCO Finland
Resection of lesion of spinal canal
277.8
26.0
26
*
NA2DG
NOMESCO Finland
Thoracal spine very extensive MRI examination with high intensity magnet
100.2
26.0
28
*
9560/0-C72.0
ICD-O-3
Schwannoma, NOS, of spinal cord
+∞
24.2
23
*
2254A
ICD-9 Finland
Benign neoplasm of brain and other parts of nervous system, Spinal meninges
+∞
23.1
22
*
N03AX12
ATC
[U] gabapentin; oral
3.2
23.0
116
450
D43.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Spinal cord
+∞
22.1
21
*
ZXE20
NOMESCO Finland
More than three and less than five hours
3.4
21.8
97
348
D33.43
ICD-10 Finland
Spinal cord
+∞
21.0
20
*
WX408
NOMESCO Finland
General anesthesy, balanced
2.8
20.5
150
709
8000/0-C70.1
ICD-O-3
Neoplasm, benign of spinal meninges
+∞
20.0
19
*
NA7FT
NOMESCO Finland
Labeling lesion in spinal area with X-ray guidance
210.1
19.7
20
*
N03AX16
ATC
[U] pregabalin
2.7
19.3
142
670
2312
FHL
Extirpation or destruction
+∞
18.9
18
*
D33.4
ICD-10 Finland
Benign neoplasm: Spinal cord
+∞
18.9
18
*
D32.07
ICD-10 Finland
Secondary or multiple benign tumor of the meninges below the exam
177.2
16.6
17
*
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
3.9
16.6
53
151
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
14.6
15.7
26
19
D33.40
ICD-10 Finland
Benign glioma of the spinal cord (grade I)
+∞
15.7
15
*
G992, D321,
ICD-10 Finland
+∞
15.7
15
*
G82.2
ICD-10 Finland
Paraplegia, unspecified
23.2
15.7
22
10
R20.2
ICD-10 Finland
Paraesthesia of skin
3.7
15.5
53
158
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.1
15.1
74
277
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.2
14.7
64
223
N75
ICPC
Benign neoplasm nervous system
+∞
14.7
14
*
D32.0
ICD-10 Finland
Benign neoplasm: Cerebral meninges
44.2
14.2
17
*
L28
ICPC
Limited function/disability (L)
2.4
14.0
123
617
AA1BD
NOMESCO Finland
Extensive CT of head and brain
6.3
14.0
24
40
9531/0-C70.1
ICD-O-3
Meningothelial meningioma of spinal meninges
+∞
13.6
13
*
N18
ICPC
Paralysis/weakness
6.4
13.1
22
36
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
5.9
13.0
24
43
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
4.3
12.9
35
88
M03BX01
ATC
baclofen; systemic
5.9
12.6
23
41
AWB00
NOMESCO Finland
Reoperation for superficial infection in surgery of the nervous system
134.1
12.5
13
*
9537/0-C70.1
ICD-O-3
Transitional meningioma of spinal meninges
+∞
11.5
11
*
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
16.1
10.9
17
11
D32.02
ICD-10 Finland
Benign tumor of the meninges at the base of the brain
11.0
10.9
20
19
N06AX21
ATC
duloxetine; oral
2.6
10.7
71
309
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
4.6
10.7
26
60
T81.3
ICD-10 Finland
Disruption of operation wound, not elsewhere classified
5.6
10.5
20
37
D42.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Spinal meninges
+∞
10.5
10
*
D33.7
ICD-10 Finland
Benign neoplasm: Other specified parts of central nervous system
+∞
10.5
10
*
XKD06
NOMESCO Finland
Physiologic investigation of micturition
4.4
10.3
26
62
R4110
NOMESCO Finland
Physiotherapy
2.1
10.2
142
843
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
2.9
10.0
50
188
XKD00
NOMESCO Finland
Uroflowmetry
2.5
9.8
67
295
D33.9
ICD-10 Finland
Benign neoplasm: Central nervous system, unspecified
+∞
9.4
9
*
D33.47
ICD-10 Finland
Other benign neurofibromas in the nerve root of the spinal cord
+∞
9.4
9
*
N06AA09
ATC
amitriptyline; systemic
2.5
8.8
59
257
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
51.1
8.7
10
*
D33.30
ICD-10 Finland
Acoustic neuroma
16.7
8.6
13
8
N02AX02
ATC
tramadol; systemic, rectal
1.9
8.5
192
1325
TAA40
NOMESCO Finland
Cathetrisation of cerebrospinal fluid through skin
91.9
8.4
9
*
ZXH01
NOMESCO Finland
Procedure performed within operation theatre
91.9
8.4
9
*
Q85.01
ICD-10 Finland
Neurofibromatosis, type 2
+∞
8.4
8
*
AWC00
NOMESCO Finland
Reoperation of nervous system because of deep wound infection in the nervous system
+∞
8.4
8
*
22540
ICD-8 Finland
Benign neoplasm of brain and other parts of nervous system, Spinal meninges
+∞
8.4
8
*
D33.46
ICD-10 Finland
Benign neurofibroma in the nerve root of the spinal cord
+∞
8.4
8
*
N02BF01
ATC
gabapentin; oral
2.4
8.2
63
292
N03AX14
ATC
levetiracetam; systemic
4.7
8.2
19
42
N28
ICPC
Limited function/disability (N)
6.5
8.1
20
32
M54.4
ICD-10 Finland
Lumbago with sciatica
2.1
8.1
91
494
WX402
NOMESCO Finland
General anaesthesia
2.0
8.1
102
578
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.0
8.1
98
548
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.7
7.9
43
169
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
2.4
7.7
59
273
ZSA00
NOMESCO Finland
Procedure related to previous procedure classified in chapter A
25.6
7.6
10
*
N02BF02
ATC
pregabalin; oral
2.7
7.5
42
167
M48.0
ICD-10 Finland
Spinal stenosis
2.2
7.5
73
374
AWW99
NOMESCO Finland
Other reoperation in surgery of the nervous system
81.6
7.4
8
*
YX8VG
NOMESCO Finland
Stereotactic MRI exmaination with high intensity magnet for dose design of radiotherapy
81.6
7.4
8
*
XKC03
NOMESCO Finland
Water cystometry
3.6
7.4
24
69
D32.06
ICD-10 Finland
Benign tumor of the meninges os petrosum or clivus area
+∞
7.3
7
*
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
4.4
7.3
18
42
N02BE01
ATC
paracetamol; systemic, rectal
3.0
7.2
369
3266
AA1AD
NOMESCO Finland
CT of head and brain
1.8
7.2
140
910
YX8BD
NOMESCO Finland
Stereotactic extensive CT examination for dose design of radiotherapy
30.6
7.2
9
*
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
20.5
7.2
10
5
M54.2
ICD-10 Finland
Cervicalgia
2.6
7.1
43
179
ZXD35
NOMESCO Finland
Usual procedure
3.8
7.0
21
57
ZXE10
NOMESCO Finland
More than one and less than three hours
1.8
6.9
160
1096
D32.04
ICD-10 Finland
Secondary or multiple benign tumor of the meninges above the exam
23.0
6.7
9
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.0
6.7
80
443
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
10.3
6.6
12
12
NA1AA
NOMESCO Finland
Cervical spine X-ray examination without contrast
3.5
6.5
22
65
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
3.3
6.4
24
76
AAK00
NOMESCO Finland
Cranioplasty
+∞
6.3
6
*
9533/0-C70.1
ICD-O-3
Psammomatous meningioma of spinal meninges
+∞
6.3
6
*
9539/1-C70.0
ICD-O-3
Atypical meningioma of cerebral meninges
+∞
6.3
6
*
9539/1-C70.1
ICD-O-3
Atypical meningioma of spinal meninges
+∞
6.3
6
*
ABC63
NOMESCO Finland
Decompression of thoracic spinal cord
27.1
6.2
8
*
NA1DG
NOMESCO Finland
Cervical spine very extensive MRI examination with high intensity magnet
27.1
6.2
8
*
H02AB02
ATC
dexamethasone; systemic
2.1
6.2
63
328
WX110
NOMESCO Finland
Infiltration anesthesia
1.8
6.1
282
2308
ZXC40
NOMESCO Finland
Use of ultrasound
12.8
6.1
10
8
M54.6
ICD-10 Finland
Pain in thoracic spine
2.5
6.0
39
167

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Neurosurgery
14 [38004459]
2.1e+00
2.9e+00
—
—
5.9e+00
5.4e+00
3.8e+00
cases:16.28%
controls:2.30%
cases:15.76%
controls:0.98%
—
—
—
—
cases:31.61%
controls:0.13%
cases:65.95%
controls:0.88%
cases:54.29%
controls:2.69%
63
89
324
3781
61
38
326
3832
—
—
122
5
264
3856
244
33
126
3711
171
86
144
3115
Oncology Clinic/Center
261QX0200X [38004268]
1.1e+00
2.2e+00
3.9e+00
1.0e+50
5.2e+00
2.5e+00
7.2e-01
cases:15.25%
controls:5.89%
cases:13.18%
controls:1.68%
cases:12.40%
controls:0.28%
cases:7.75%
controls:0.00%
cases:18.39%
controls:0.13%
cases:14.32%
controls:1.36%
cases:11.43%
controls:5.94%
59
228
328
3642
51
65
336
3805
48
11
339
3859
30
0
357
3870
71
5
315
3856
53
51
317
3693
36
190
279
3011
Neurology
13 [38004458]
9.4e-01
1.9e+00
3.0e+00
1.0e+50
3.2e+00
2.1e+00
1.4e+00
cases:22.48%
controls:10.21%
cases:24.55%
controls:4.57%
cases:14.73%
controls:0.83%
cases:16.80%
controls:0.00%
cases:13.73%
controls:0.67%
cases:26.22%
controls:4.17%
cases:33.33%
controls:11.31%
87
395
300
3475
95
177
292
3693
57
32
330
3838
65
0
322
3870
53
26
333
3835
97
156
273
3588
105
362
210
2839
Outpatient Visit
OP [9202]
3.2e-01
8.9e-01
1.2e+00
4.8e+00
1.2e+00
1.5e+00
9.8e-01
cases:77.52%
controls:71.47%
cases:72.61%
controls:52.12%
cases:28.17%
controls:10.36%
cases:43.67%
controls:0.62%
cases:29.27%
controls:10.93%
cases:81.89%
controls:50.59%
cases:89.84%
controls:76.79%
300
2766
87
1104
281
2017
106
1853
109
401
278
3469
169
24
218
3846
113
422
273
3439
303
1894
67
1850
283
2458
32
743
Physical Medicine And Rehabilitation
25 [38004468]
7.4e-01
1.7e+00
2.3e+00
1.0e+50
2.4e+00
2.1e+00
1.2e+00
cases:13.44%
controls:6.87%
cases:11.63%
controls:2.30%
cases:3.88%
controls:0.41%
cases:1.55%
controls:0.00%
cases:4.15%
controls:0.39%
cases:15.68%
controls:2.19%
cases:20.95%
controls:7.09%
52
266
335
3604
45
89
342
3781
15
16
372
3854
6
0
381
3870
16
15
370
3846
58
82
312
3662
66
227
249
2974
Benign tumor of the meninges on the outer surface of the cerebrum
D32.00 [2000501307]
3.4e+00
1.0e+50
1.0e+50
1.0e+50
1.0e+50
3.7e+00
3.3e+00
cases:3.88%
controls:0.13%
cases:4.13%
controls:0.00%
cases:1.29%
controls:0.00%
cases:1.55%
controls:0.00%
cases:1.30%
controls:0.00%
cases:5.14%
controls:0.13%
cases:7.30%
controls:0.28%
15
5
372
3865
16
0
371
3870
5
0
382
3870
6
0
381
3870
5
0
381
3861
19
5
351
3739
23
9
292
3192
pregabalin; oral
N02BF02 [955152]
1.0e+00
1.6e+00
1.9e+00
—
2.0e+00
1.8e+00
1.4e+00
cases:9.82%
controls:3.80%
cases:10.34%
controls:2.27%
cases:4.65%
controls:0.72%
—
—
cases:5.44%
controls:0.75%
cases:10.54%
controls:1.95%
cases:14.92%
controls:3.97%
38
147
349
3723
40
88
347
3782
18
28
369
3842
—
21
29
365
3832
39
73
331
3671
47
127
268
3074
Outpatient Hospital
22 [8756]
4.7e-01
9.2e-01
2.2e+00
—
3.3e+00
1.7e+00
5.1e-01
cases:34.37%
controls:24.65%
cases:16.80%
controls:7.42%
cases:7.24%
controls:0.83%
—
—
cases:19.69%
controls:0.88%
cases:24.86%
controls:5.88%
cases:26.35%
controls:17.65%
133
954
254
2916
65
287
322
3583
28
32
359
3838
—
76
34
310
3827
92
220
278
3524
83
565
232
2636
Scheduled procedure
ZXD10 [2001311387]
5.9e-01
1.4e+00
1.8e+00
—
3.7e+00
1.8e+00
1.0e+00
cases:10.85%
controls:6.30%
cases:5.94%
controls:1.47%
cases:1.29%
controls:0.21%
—
—
cases:5.96%
controls:0.16%
cases:6.76%
controls:1.20%
cases:9.52%
controls:3.69%
42
244
345
3626
23
57
364
3813
5
8
382
3862
—
23
6
363
3855
25
45
345
3699
30
118
285
3083
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
7.9e-01
1.4e+00
2.2e+00
—
1.9e+00
1.3e+00
8.6e-01
cases:14.47%
controls:7.13%
cases:10.34%
controls:2.74%
cases:4.13%
controls:0.47%
—
—
cases:3.89%
controls:0.60%
cases:8.92%
controls:2.56%
cases:13.97%
controls:6.44%
56
276
331
3594
40
106
347
3764
16
18
371
3852
—
15
23
371
3838
33
96
337
3648
44
206
271
2995
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
6.6e-02
3.8e-01
1.1e+00
4.1e+00
1.7e+00
5.1e-01
2.0e-01
cases:34.37%
controls:32.89%
cases:34.11%
controls:26.12%
cases:13.18%
controls:4.88%
cases:7.49%
controls:0.13%
cases:20.73%
controls:4.61%
cases:38.92%
controls:27.64%
cases:51.75%
controls:46.80%
133
1273
254
2597
132
1011
255
2859
51
189
336
3681
29
5
358
3865
80
178
306
3683
144
1035
226
2709
163
1498
152
1703
Inpatient Hospital
21 [8717]
2.9e-01
8.7e-01
2.4e+00
—
3.2e+00
1.3e+00
4.0e-01
cases:36.69%
controls:30.21%
cases:21.45%
controls:10.23%
cases:12.92%
controls:1.34%
—
—
cases:24.87%
controls:1.35%
cases:27.57%
controls:9.00%
cases:31.11%
controls:23.15%
142
1169
245
2701
83
396
304
3474
50
52
337
3818
—
96
52
290
3809
102
337
268
3407
98
741
217
2460
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
6.6e-02
6.0e-01
1.2e+00
3.5e+00
1.7e+00
7.3e-01
2.3e-01
cases:29.46%
controls:28.11%
cases:29.20%
controls:18.42%
cases:11.37%
controls:3.82%
cases:5.94%
controls:0.18%
cases:18.39%
controls:3.89%
cases:34.32%
controls:20.11%
cases:45.08%
controls:39.36%
114
1088
273
2782
113
713
274
3157
44
148
343
3722
23
7
364
3863
71
150
315
3711
127
753
243
2991
142
1260
173
1941
Inpatient Visit
IP [9201]
7.2e-03
7.5e-01
2.3e+00
—
3.5e+00
1.4e+00
6.0e-01
cases:7.75%
controls:7.70%
cases:6.20%
controls:3.02%
cases:3.62%
controls:0.39%
—
—
cases:10.36%
controls:0.36%
cases:10.27%
controls:2.80%
cases:15.56%
controls:9.18%
30
298
357
3572
24
117
363
3753
14
15
373
3855
—
40
14
346
3847
38
105
332
3639
49
294
266
2907
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
4.8e-02
3.6e-01
1.1e+00
4.1e+00
1.6e+00
5.0e-01
1.9e-01
cases:34.11%
controls:33.05%
cases:34.11%
controls:26.46%
cases:13.70%
controls:4.99%
cases:7.24%
controls:0.13%
cases:20.47%
controls:4.71%
cases:39.19%
controls:28.15%
cases:51.75%
controls:47.11%
132
1279
255
2591
132
1024
255
2846
53
193
334
3677
28
5
359
3865
79
182
307
3679
145
1054
225
2690
163
1508
152
1693
gabapentin; oral
N02BF01 [955005]
8.8e-01
1.3e+00
1.6e+00
—
1.3e+00
2.0e+00
1.0e+00
cases:5.94%
controls:2.56%
cases:6.46%
controls:1.81%
cases:2.33%
controls:0.47%
—
—
cases:2.07%
controls:0.57%
cases:8.65%
controls:1.31%
cases:12.06%
controls:4.59%
23
99
364
3771
25
70
362
3800
9
18
378
3852
—
8
22
378
3839
32
49
338
3695
38
147
277
3054
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
4.1e-02
3.7e-01
1.1e+00
3.8e+00
1.4e+00
5.1e-01
1.7e-01
cases:35.66%
controls:34.73%
cases:38.24%
controls:30.05%
cases:16.54%
controls:6.20%
cases:7.75%
controls:0.18%
cases:20.47%
controls:6.03%
cases:43.24%
controls:31.44%
cases:54.29%
controls:50.11%
138
1344
249
2526
148
1163
239
2707
64
240
323
3630
30
7
357
3863
79
233
307
3628
160
1177
210
2567
171
1604
144
1597
Physiotherapy
R4110 [2001310233]
4.1e-01
1.0e+00
1.6e+00
1.0e+50
3.7e+00
1.8e+00
7.4e-01
cases:6.98%
controls:4.75%
cases:4.65%
controls:1.76%
cases:1.55%
controls:0.31%
cases:5.68%
controls:0.00%
cases:8.81%
controls:0.23%
cases:9.19%
controls:1.58%
cases:7.94%
controls:3.97%
27
184
360
3686
18
68
369
3802
6
12
381
3858
22
0
365
3870
34
9
352
3852
34
59
336
3685
25
127
290
3074
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
1.2e+00
2.7e+00
—
1.0e+50
—
—
2.6e+00
cases:3.62%
controls:1.11%
cases:4.13%
controls:0.28%
—
—
cases:3.36%
controls:0.00%
—
—
—
—
cases:11.11%
controls:0.94%
14
43
373
3827
16
11
371
3859
—
13
0
374
3870
—
—
35
30
280
3171
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
-5.6e-03
2.9e-01
1.0e+00
3.7e+00
1.2e+00
4.9e-01
3.7e-01
cases:24.29%
controls:24.39%
cases:26.10%
controls:20.90%
cases:10.85%
controls:4.13%
cases:4.91%
controls:0.13%
cases:13.73%
controls:4.38%
cases:31.62%
controls:22.14%
cases:46.03%
controls:36.99%
94
944
293
2926
101
809
286
3061
42
160
345
3710
19
5
368
3865
53
169
333
3692
117
829
253
2915
145
1184
170
2017
Platelets [#/volume] in Blood
26515-7 [3007461]
7.4e-02
3.1e-01
8.8e-01
3.9e+00
1.3e+00
3.8e-01
9.4e-02
cases:38.24%
controls:36.51%
cases:39.02%
controls:32.04%
cases:16.28%
controls:7.47%
cases:8.01%
controls:0.18%
cases:21.76%
controls:6.99%
cases:43.24%
controls:34.19%
cases:54.60%
controls:52.26%
148
1413
239
2457
151
1240
236
2630
63
289
324
3581
31
7
356
3863
84
270
302
3591
160
1280
210
2464
172
1673
143
1528
MCH [Entitic mass]
28539-5 [3035941]
7.0e-02
3.0e-01
8.8e-01
3.9e+00
1.3e+00
3.8e-01
9.0e-02
cases:38.24%
controls:36.61%
cases:39.02%
controls:32.07%
cases:16.28%
controls:7.49%
cases:8.01%
controls:0.18%
cases:21.76%
controls:7.04%
cases:43.24%
controls:34.29%
cases:54.60%
controls:52.36%
148
1417
239
2453
151
1241
236
2629
63
290
324
3580
31
7
356
3863
84
272
302
3589
160
1284
210
2460
172
1676
143
1525
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
6.8e-02
3.1e-01
8.8e-01
3.9e+00
1.3e+00
3.8e-01
9.0e-02
cases:38.24%
controls:36.64%
cases:39.02%
controls:32.04%
cases:16.28%
controls:7.49%
cases:8.01%
controls:0.18%
cases:21.76%
controls:7.04%
cases:43.24%
controls:34.32%
cases:54.60%
controls:52.36%
148
1418
239
2452
151
1240
236
2630
63
290
324
3580
31
7
356
3863
84
272
302
3589
160
1285
210
2459
172
1676
143
1525
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
6.8e-02
3.0e-01
8.8e-01
3.9e+00
1.3e+00
3.7e-01
8.9e-02
cases:38.24%
controls:36.64%
cases:39.02%
controls:32.07%
cases:16.28%
controls:7.49%
cases:8.01%
controls:0.18%
cases:21.76%
controls:7.04%
cases:43.24%
controls:34.38%
cases:54.60%
controls:52.39%
148
1418
239
2452
151
1241
236
2629
63
290
324
3580
31
7
356
3863
84
272
302
3589
160
1287
210
2457
172
1677
143
1524
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
6.8e-02
3.0e-01
8.7e-01
3.9e+00
1.3e+00
3.7e-01
8.8e-02
cases:38.24%
controls:36.64%
cases:39.02%
controls:32.12%
cases:16.28%
controls:7.52%
cases:8.01%
controls:0.18%
cases:21.76%
controls:7.04%
cases:43.24%
controls:34.38%
cases:54.60%
controls:52.42%
148
1418
239
2452
151
1243
236
2627
63
291
324
3579
31
7
356
3863
84
272
302
3589
160
1287
210
2457
172
1678
143
1523
Leukocytes [#/volume] in Blood
26464-8 [3010813]
7.9e-02
3.0e-01
8.7e-01
3.9e+00
1.3e+00
3.7e-01
8.8e-02
cases:38.50%
controls:36.64%
cases:39.02%
controls:32.14%
cases:16.28%
controls:7.55%
cases:8.01%
controls:0.18%
cases:21.76%
controls:7.07%
cases:43.24%
controls:34.38%
cases:54.60%
controls:52.42%
149
1418
238
2452
151
1244
236
2626
63
292
324
3578
31
7
356
3863
84
273
302
3588
160
1287
210
2457
172
1678
143
1523
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
6.8e-02
3.0e-01
8.8e-01
3.7e+00
1.3e+00
3.9e-01
8.9e-02
cases:38.24%
controls:36.64%
cases:39.02%
controls:32.12%
cases:16.28%
controls:7.49%
cases:8.01%
controls:0.21%
cases:22.02%
controls:7.04%
cases:43.51%
controls:34.35%
cases:54.60%
controls:52.39%
148
1418
239
2452
151
1243
236
2627
63
290
324
3580
31
8
356
3862
85
272
301
3589
161
1286
209
2458
172
1677
143
1524
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
2.9e-01
3.2e-01
2.3e+00
1.0e+50
2.7e+00
1.3e+00
4.4e-01
cases:6.46%
controls:4.94%
cases:3.62%
controls:2.66%
cases:4.65%
controls:0.49%
cases:4.39%
controls:0.00%
cases:5.70%
controls:0.39%
cases:8.92%
controls:2.70%
cases:9.52%
controls:6.34%
25
191
362
3679
14
103
373
3767
18
19
369
3851
17
0
370
3870
22
15
364
3846
33
101
337
3643
30
203
285
2998
Emergency Room Visit
ER [9203]
3.4e-01
8.3e-01
2.3e+00
—
1.9e+00
8.0e-01
4.2e-01
cases:38.76%
controls:31.01%
cases:22.74%
controls:11.34%
cases:11.37%
controls:1.32%
—
—
cases:9.84%
controls:1.66%
cases:22.43%
controls:11.51%
cases:36.19%
controls:27.05%
150
1200
237
2670
88
439
299
3431
44
51
343
3819
—
38
64
348
3797
83
431
287
3313
114
866
201
2335
General Surgery
2 [38004447]
2.8e-01
8.2e-01
1.7e+00
—
1.8e+00
1.2e+00
5.9e-01
cases:23.00%
controls:18.48%
cases:12.40%
controls:5.87%
cases:5.17%
controls:0.98%
—
—
cases:5.18%
controls:0.93%
cases:15.41%
controls:5.34%
cases:24.13%
controls:15.03%
89
715
298
3155
48
227
339
3643
20
38
367
3832
—
20
36
366
3825
57
200
313
3544
76
481
239
2720
Intravenous general anesthesia
WX404 [2001310807]
3.1e-01
7.9e-01
—
1.0e+50
2.5e+00
2.0e+00
1.5e+00
cases:4.39%
controls:3.26%
cases:1.81%
controls:0.83%
—
—
cases:1.81%
controls:0.00%
cases:2.07%
controls:0.18%
cases:3.51%
controls:0.48%
cases:6.35%
controls:1.44%
17
126
370
3744
7
32
380
3838
—
7
0
380
3870
8
7
378
3854
13
18
357
3726
20
46
295
3155
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
1.9e-01
3.7e-01
1.6e+00
—
2.9e+00
1.5e+00
3.8e-01
cases:9.82%
controls:8.29%
cases:5.43%
controls:3.80%
cases:2.33%
controls:0.47%
—
—
cases:5.70%
controls:0.34%
cases:12.16%
controls:3.13%
cases:14.60%
controls:10.47%
38
321
349
3549
21
147
366
3723
9
18
378
3852
—
22
13
364
3848
45
117
325
3627
46
335
269
2866
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
1.0e-01
5.4e-01
2.0e+00
1.0e+50
2.7e+00
1.2e+00
2.4e-01
cases:12.66%
controls:11.55%
cases:9.56%
controls:5.79%
cases:6.20%
controls:0.85%
cases:3.62%
controls:0.00%
cases:8.81%
controls:0.67%
cases:17.57%
controls:6.06%
cases:21.90%
controls:18.06%
49
447
338
3423
37
224
350
3646
24
33
363
3837
14
0
373
3870
34
26
352
3835
65
227
305
3517
69
578
246
2623
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
9.9e-03
1.3e-01
9.1e-01
3.6e+00
1.3e+00
1.6e-01
2.0e-02
cases:24.29%
controls:24.11%
cases:22.22%
controls:20.03%
cases:11.11%
controls:4.81%
cases:4.65%
controls:0.13%
cases:14.25%
controls:4.38%
cases:24.32%
controls:21.45%
cases:34.92%
controls:34.46%
94
933
293
2937
86
775
301
3095
43
186
344
3684
18
5
369
3865
55
169
331
3692
90
803
280
2941
110
1103
205
2098
dexamethasone; oral, parenteral
H02AB02 [21602730]
2.7e-01
1.2e+00
2.1e+00
—
2.5e+00
1.0e+00
5.8e-01
cases:3.62%
controls:2.79%
cases:3.62%
controls:1.11%
cases:1.81%
controls:0.23%
—
—
cases:3.11%
controls:0.26%
cases:3.24%
controls:1.18%
cases:6.35%
controls:3.66%
14
108
373
3762
14
43
373
3827
7
9
380
3861
—
12
10
374
3851
12
44
358
3700
20
117
295
3084
Cervicalgia
M54.2 [45591867]
6.7e-01
2.0e+00
—
—
—
2.3e+00
1.4e+00
cases:1.55%
controls:0.80%
cases:1.81%
controls:0.26%
—
—
—
—
—
—
cases:1.89%
controls:0.19%
cases:3.49%
controls:0.87%
6
31
381
3839
7
10
380
3860
—
—
—
7
7
363
3737
11
28
304
3173
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
2.3e-01
4.6e-01
1.9e+00
1.0e+50
3.4e+00
1.5e+00
6.8e-01
cases:7.49%
controls:6.02%
cases:3.88%
controls:2.48%
cases:1.55%
controls:0.23%
cases:4.65%
controls:0.00%
cases:6.48%
controls:0.23%
cases:9.73%
controls:2.32%
cases:13.02%
controls:7.03%
29
233
358
3637
15
96
372
3774
6
9
381
3861
18
0
369
3870
25
9
361
3852
36
87
334
3657
41
225
274
2976
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
3.8e-01
7.8e-01
1.4e+00
—
2.3e+00
1.1e+00
2.9e-01
cases:13.18%
controls:9.43%
cases:11.11%
controls:5.40%
cases:3.10%
controls:0.78%
—
—
cases:7.51%
controls:0.83%
cases:13.78%
controls:5.02%
cases:18.73%
controls:14.68%
51
365
336
3505
43
209
344
3661
12
30
375
3840
—
29
32
357
3829
51
188
319
3556
59
470
256
2731
duloxetine; oral
N06AX21 [21604749]
1.4e+00
1.3e+00
—
—
—
1.4e+00
1.4e+00
cases:5.94%
controls:1.52%
cases:3.62%
controls:0.98%
—
—
—
—
—
—
cases:4.59%
controls:1.12%
cases:7.62%
controls:2.09%
23
59
364
3811
14
38
373
3832
—
—
—
17
42
353
3702
24
67
291
3134
Office Visit
OMOP4822458 [581477]
2.7e-01
1.1e+00
—
1.0e+50
2.8e+00
1.7e+00
4.8e-01
cases:10.34%
controls:8.09%
cases:6.20%
controls:2.12%
—
—
cases:1.55%
controls:0.00%
cases:4.66%
controls:0.31%
cases:10.27%
controls:2.14%
cases:10.16%
controls:6.56%
40
313
347
3557
24
82
363
3788
—
6
0
381
3870
18
12
368
3849
38
80
332
3664
32
210
283
2991
Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]
8.5e-01
1.8e+00
—
1.0e+50
—
1.8e+00
1.7e+00
cases:3.10%
controls:1.34%
cases:2.07%
controls:0.36%
—
—
cases:1.29%
controls:0.00%
—
—
cases:2.43%
controls:0.40%
cases:4.76%
controls:0.87%
12
52
375
3818
8
14
379
3856
—
5
0
382
3870
—
9
15
361
3729
15
28
300
3173
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
3.3e-01
6.9e-01
1.4e+00
—
2.0e+00
9.4e-01
3.0e-01
cases:13.95%
controls:10.47%
cases:12.14%
controls:6.49%
cases:3.62%
controls:0.93%
—
—
cases:7.77%
controls:1.11%
cases:14.32%
controls:6.14%
cases:21.59%
controls:16.96%
54
405
333
3465
47
251
340
3619
14
36
373
3834
—
30
43
356
3818
53
230
317
3514
68
543
247
2658
Immunohistochemistry procedure
117617002 [4035726]
6.6e-01
1.5e+00
—
—
—
2.1e+00
1.3e+00
cases:3.36%
controls:1.76%
cases:2.33%
controls:0.52%
—
—
—
—
—
—
cases:1.89%
controls:0.24%
cases:4.76%
controls:1.41%
13
68
374
3802
9
20
378
3850
—
—
—
7
9
363
3735
15
45
300
3156
Tissue Pathology biopsy report
66121-5 [40768804]
4.2e-01
7.8e-01
—
—
3.6e+00
1.3e+00
3.4e-01
cases:12.66%
controls:8.73%
cases:5.94%
controls:2.82%
—
—
—
—
cases:9.07%
controls:0.28%
cases:8.65%
controls:2.51%
cases:13.02%
controls:9.62%
49
338
338
3532
23
109
364
3761
—
—
35
11
351
3850
32
94
338
3650
41
308
274
2893
oxycodone and naloxone; oral
N02AA55 [21604265]
3.8e-01
4.2e-01
-1.0e+50
—
2.6e+00
1.3e+00
8.7e-01
cases:3.36%
controls:2.33%
cases:1.29%
controls:0.85%
cases:0.00%
controls:0.13%
—
—
cases:2.07%
controls:0.16%
cases:3.51%
controls:0.93%
cases:6.98%
controls:3.06%
13
90
374
3780
5
33
382
3837
0
5
387
3865
—
8
6
378
3855
13
35
357
3709
22
98
293
3103
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
8.4e-01
1.4e+00
2.6e+00
—
2.1e+00
8.5e-01
4.6e-01
cases:10.34%
controls:4.75%
cases:8.53%
controls:2.22%
cases:3.88%
controls:0.31%
—
—
cases:1.30%
controls:0.16%
cases:4.32%
controls:1.90%
cases:12.70%
controls:8.43%
40
184
347
3686
33
86
354
3784
15
12
372
3858
—
5
6
381
3855
16
71
354
3673
40
270
275
2931
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
4.5e-02
9.6e-01
—
—
3.0e+00
1.8e+00
-5.6e-02
cases:1.81%
controls:1.73%
cases:2.58%
controls:1.01%
—
—
—
—
cases:3.37%
controls:0.18%
cases:4.86%
controls:0.80%
cases:3.49%
controls:3.69%
7
67
380
3803
10
39
377
3831
—
—
13
7
373
3854
18
30
352
3714
11
118
304
3083
Orthopedic Surgery
20 [38004465]
4.6e-01
5.6e-01
1.3e+00
—
1.5e+00
1.0e+00
5.6e-01
cases:20.16%
controls:13.80%
cases:10.59%
controls:6.33%
cases:3.62%
controls:1.06%
—
—
cases:4.40%
controls:1.06%
cases:13.51%
controls:5.34%
cases:24.44%
controls:15.65%
78
534
309
3336
41
245
346
3625
14
41
373
3829
—
17
41
369
3820
50
200
320
3544
77
501
238
2700
Supplier / Service Provider
OMOP5117446 [33004]
-9.4e-01
-4.1e-01
2.8e-01
—
—
2.9e+00
2.8e+00
cases:12.14%
controls:26.05%
cases:6.20%
controls:9.04%
cases:1.29%
controls:0.98%
—
—
—
—
cases:9.73%
controls:0.61%
cases:16.83%
controls:1.22%
47
1008
340
2862
24
350
363
3520
5
38
382
3832
—
—
36
23
334
3721
53
39
262
3162
Paraesthesia of skin
R20.2 [45568120]
2.1e+00
2.6e+00
—
—
—
—
1.4e+00
cases:2.58%
controls:0.31%
cases:3.62%
controls:0.28%
—
—
—
—
—
—
—
—
cases:2.54%
controls:0.66%
10
12
377
3858
14
11
373
3859
—
—
—
—
8
21
307
3180
amitriptyline; oral, parenteral
N06AA09 [21604696]
7.8e-01
1.5e+00
1.3e+00
—
1.2e+00
1.2e+00
1.2e+00
cases:8.79%
controls:4.21%
cases:8.01%
controls:1.94%
cases:1.81%
controls:0.52%
—
—
cases:1.55%
controls:0.49%
cases:5.95%
controls:1.90%
cases:13.65%
controls:4.37%
34
163
353
3707
31
75
356
3795
7
20
380
3850
—
6
19
380
3842
22
71
348
3673
43
140
272
3061
Laboratory Visit
OMOP4822461 [32036]
2.7e-02
2.7e-01
7.2e-01
2.8e+00
1.1e+00
2.9e-01
7.5e-02
cases:40.57%
controls:39.92%
cases:45.22%
controls:38.60%
cases:23.51%
controls:13.02%
cases:9.82%
controls:0.65%
cases:29.02%
controls:12.20%
cases:47.84%
controls:40.63%
cases:58.10%
controls:56.26%
157
1545
230
2325
175
1494
212
2376
91
504
296
3366
38
25
349
3845
112
471
274
3390
177
1521
193
2223
183
1801
132
1400
General anesthesia, balanced
WX408 [2001310808]
8.9e-01
1.4e+00
—
1.0e+50
—
2.3e+00
9.2e-01
cases:8.01%
controls:3.46%
cases:4.39%
controls:1.09%
—
—
cases:5.94%
controls:0.00%
—
—
cases:6.49%
controls:0.72%
cases:4.44%
controls:1.81%
31
134
356
3736
17
42
370
3828
—
23
0
364
3870
—
24
27
346
3717
14
58
301
3143
Psychiatry
26 [38004469]
4.4e-01
9.7e-01
1.1e+00
—
1.4e+00
1.2e+00
9.8e-01
cases:5.94%
controls:3.93%
cases:4.65%
controls:1.81%
cases:1.81%
controls:0.59%
—
—
cases:2.59%
controls:0.65%
cases:5.68%
controls:1.76%
cases:9.21%
controls:3.66%
23
152
364
3718
18
70
369
3800
7
23
380
3847
—
10
25
376
3836
21
66
349
3678
29
117
286
3084
tizanidine; oral
M03BX02 [21604116]
3.4e-01
1.3e+00
1.5e+00
—
1.2e+00
1.0e+00
7.4e-01
cases:15.76%
controls:11.78%
cases:11.89%
controls:3.64%
cases:2.33%
controls:0.52%
—
—
cases:1.55%
controls:0.49%
cases:9.19%
controls:3.61%
cases:19.05%
controls:10.09%
61
456
326
3414
46
141
341
3729
9
20
378
3850
—
6
19
380
3842
34
135
336
3609
60
323
255
2878
ABO and Rh group [Type] in Blood
882-1 [3003694]
3.8e-01
—
2.9e+00
—
—
1.6e+00
-2.7e-02
cases:5.68%
controls:3.95%
—
—
cases:2.33%
controls:0.13%
—
—
—
—
cases:4.05%
controls:0.85%
cases:4.44%
controls:4.56%
22
153
365
3717
—
9
5
378
3865
—
—
15
32
355
3712
14
146
301
3055
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
8.7e-01
—
-1.0e+50
—
—
3.1e+00
1.4e+00
cases:1.29%
controls:0.54%
—
—
cases:0.00%
controls:0.18%
—
—
—
—
cases:3.51%
controls:0.16%
cases:3.81%
controls:1.00%
5
21
382
3849
—
0
7
387
3863
—
—
13
6
357
3738
12
32
303
3169
Case Management Agency
251B00000X [38004193]
2.2e-03
1.5e-01
5.7e-01
3.3e+00
6.1e-01
1.5e-01
1.8e-01
cases:62.27%
controls:62.22%
cases:60.21%
controls:56.54%
cases:35.14%
controls:23.44%
cases:26.10%
controls:1.29%
cases:36.27%
controls:23.57%
cases:61.89%
controls:58.31%
cases:77.78%
controls:74.60%
241
2408
146
1462
233
2188
154
1682
136
907
251
2963
101
50
286
3820
140
910
246
2951
229
2183
141
1561
245
2388
70
813
Polyneuropathy, unspecified
G62.9 [45566898]
1.4e+00
2.5e+00
—
—
—
—
2.0e+00
cases:1.29%
controls:0.31%
cases:1.55%
controls:0.13%
—
—
—
—
—
—
—
—
cases:2.22%
controls:0.31%
5
12
382
3858
6
5
381
3865
—
—
—
—
7
10
308
3191
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
3.0e-01
6.3e-01
7.4e-01
—
1.8e+00
7.9e-01
5.1e-01
cases:43.67%
controls:36.43%
cases:32.56%
controls:20.47%
cases:7.49%
controls:3.72%
—
—
cases:17.88%
controls:3.44%
cases:37.30%
controls:21.31%
cases:54.29%
controls:41.61%
169
1410
218
2460
126
792
261
3078
29
144
358
3726
—
69
133
317
3728
138
798
232
2946
171
1332
144
1869
Spinal stenosis
M48.0 [45557888]
6.3e-01
1.6e+00
2.8e+00
1.0e+50
—
7.2e-01
5.3e-01
cases:3.36%
controls:1.81%
cases:4.39%
controls:0.88%
cases:3.62%
controls:0.23%
cases:2.07%
controls:0.00%
—
—
cases:2.43%
controls:1.20%
cases:4.13%
controls:2.47%
13
70
374
3800
17
34
370
3836
14
9
373
3861
8
0
379
3870
—
9
45
361
3699
13
79
302
3122
venlafaxine; oral
N06AX16 [21604745]
7.7e-01
1.4e+00
—
—
—
1.7e+00
1.3e+00
cases:4.39%
controls:2.09%
cases:3.88%
controls:1.03%
—
—
—
—
—
—
cases:5.14%
controls:0.93%
cases:5.71%
controls:1.62%
17
81
370
3789
15
40
372
3830
—
—
—
19
35
351
3709
18
52
297
3149
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
4.6e-01
6.5e-01
—
1.0e+50
2.8e+00
1.5e+00
6.0e-01
cases:5.94%
controls:3.85%
cases:2.84%
controls:1.50%
—
—
cases:2.84%
controls:0.00%
cases:3.63%
controls:0.23%
cases:8.11%
controls:1.84%
cases:8.25%
controls:4.69%
23
149
364
3721
11
58
376
3812
—
11
0
376
3870
14
9
372
3852
30
69
340
3675
26
150
289
3051
Ophthalmology
18 [38004463]
1.7e-01
5.2e-01
8.5e-01
3.0e+00
1.1e-01
6.9e-01
5.8e-01
cases:20.93%
controls:18.22%
cases:11.63%
controls:7.26%
cases:3.10%
controls:1.34%
cases:2.58%
controls:0.13%
cases:1.55%
controls:1.40%
cases:14.59%
controls:7.88%
cases:30.16%
controls:19.40%
81
705
306
3165
45
281
342
3589
12
52
375
3818
10
5
377
3865
6
54
380
3807
54
295
316
3449
95
621
220
2580
Low back pain
M54.5 [45553207]
8.9e-01
1.2e+00
2.2e+00
—
—
5.1e-01
3.7e-01
cases:11.63%
controls:5.12%
cases:6.72%
controls:2.04%
cases:1.55%
controls:0.18%
—
—
—
—
cases:4.32%
controls:2.64%
cases:10.16%
controls:7.25%
45
198
342
3672
26
79
361
3791
6
7
381
3863
—
—
16
99
354
3645
32
232
283
2969
Respiratory and circulatory monitoring
WX700 [2001310817]
4.7e-01
1.6e+00
—
1.0e+50
—
2.6e+00
4.5e-01
cases:3.36%
controls:2.12%
cases:3.62%
controls:0.72%
—
—
cases:5.94%
controls:0.00%
—
—
cases:6.49%
controls:0.51%
cases:3.49%
controls:2.25%
13
82
374
3788
14
28
373
3842
—
23
0
364
3870
—
24
19
346
3725
11
72
304
3129
General Practice
1 [38004446]
1.2e-01
5.4e-01
1.5e+00
1.0e+50
1.9e+00
7.0e-01
4.3e-01
cases:14.73%
controls:13.33%
cases:9.82%
controls:5.97%
cases:4.13%
controls:0.93%
cases:2.07%
controls:0.00%
cases:5.44%
controls:0.85%
cases:11.35%
controls:5.98%
cases:21.59%
controls:15.18%
57
516
330
3354
38
231
349
3639
16
36
371
3834
8
0
379
3870
21
33
365
3828
42
224
328
3520
68
486
247
2715
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
1.2e+00
2.0e+00
—
—
—
2.1e+00
1.3e+00
cases:3.10%
controls:0.96%
cases:1.81%
controls:0.26%
—
—
—
—
—
—
cases:1.89%
controls:0.24%
cases:3.17%
controls:0.91%
12
37
375
3833
7
10
380
3860
—
—
—
7
9
363
3735
10
29
305
3172
Removal of sutures
SPAT1153 [2001700254]
1.0e-01
-4.3e-02
—
—
2.8e+00
1.2e+00
3.0e-01
cases:6.72%
controls:6.10%
cases:1.81%
controls:1.89%
—
—
—
—
cases:2.07%
controls:0.13%
cases:4.86%
controls:1.47%
cases:7.30%
controls:5.53%
26
236
361
3634
7
73
380
3797
—
—
8
5
378
3856
18
55
352
3689
23
177
292
3024
Pharmacy visit
OMOP4822462 [581458]
4.6e-01
9.1e-01
4.6e-01
1.2e+00
6.2e-01
7.8e-01
8.6e-01
cases:94.32%
controls:91.27%
cases:93.54%
controls:85.30%
cases:62.53%
controls:51.27%
cases:6.72%
controls:2.22%
cases:64.77%
controls:49.78%
cases:93.24%
controls:86.35%
cases:98.10%
controls:95.63%
365
3532
22
338
362
3301
25
569
242
1984
145
1886
26
86
361
3784
250
1922
136
1939
345
3233
25
511
309
3061
6
140
Uroflowmetry
44856007 [4261340]
4.4e-01
—
—
—
—
2.0e+00
1.9e+00
cases:2.58%
controls:1.68%
—
—
—
—
—
—
—
—
cases:3.78%
controls:0.53%
cases:7.30%
controls:1.12%
10
65
377
3805
—
—
—
—
14
20
356
3724
23
36
292
3165
levetiracetam; oral, parenteral
N03AX14 [21604436]
—
—
—
—
—
2.1e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.27%
cases:2.54%
controls:0.47%
—
—
—
—
—
8
10
362
3734
8
15
307
3186
pH of Arterial blood
2744-1 [3019977]
5.8e-01
1.5e+00
—
—
—
2.2e+00
1.7e-01
cases:3.10%
controls:1.76%
cases:2.84%
controls:0.65%
—
—
—
—
—
—
cases:5.95%
controls:0.69%
cases:3.49%
controls:2.97%
12
68
375
3802
11
25
376
3845
—
—
—
22
26
348
3718
11
95
304
3106
Infiltration anesthesia
WX110 [2001310767]
1.0e-01
1.3e-01
9.6e-01
—
2.9e+00
7.8e-01
4.4e-01
cases:19.12%
controls:17.62%
cases:7.49%
controls:6.67%
cases:2.07%
controls:0.80%
—
—
cases:12.18%
controls:0.75%
cases:14.05%
controls:7.00%
cases:28.25%
controls:20.18%
74
682
313
3188
29
258
358
3612
8
31
379
3839
—
47
29
339
3832
52
262
318
3482
89
646
226
2555
Medical Oncology
90 [38004507]
2.3e-01
7.2e-01
3.0e-01
—
1.1e+00
8.9e-01
9.4e-01
cases:6.72%
controls:5.40%
cases:7.49%
controls:3.80%
cases:1.81%
controls:1.34%
—
—
cases:4.15%
controls:1.42%
cases:9.19%
controls:3.98%
cases:12.38%
controls:5.25%
26
209
361
3661
29
147
358
3723
7
52
380
3818
—
16
55
370
3806
34
149
336
3595
39
168
276
3033
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
6.1e-01
1.5e+00
—
—
—
2.1e+00
1.4e-01
cases:3.10%
controls:1.71%
cases:2.84%
controls:0.65%
—
—
—
—
—
—
cases:5.95%
controls:0.75%
cases:3.49%
controls:3.06%
12
66
375
3804
11
25
376
3845
—
—
—
22
28
348
3716
11
98
304
3103
Base excess in Arterial blood by calculation
1925-7 [3003396]
4.9e-01
1.5e+00
—
—
—
2.1e+00
1.6e-01
cases:2.84%
controls:1.76%
cases:2.84%
controls:0.65%
—
—
—
—
—
—
cases:5.95%
controls:0.75%
cases:3.49%
controls:3.00%
11
68
376
3802
11
25
376
3845
—
—
—
22
28
348
3716
11
96
304
3105
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
6.1e-01
1.5e+00
—
—
—
2.1e+00
1.4e-01
cases:3.10%
controls:1.71%
cases:2.84%
controls:0.65%
—
—
—
—
—
—
cases:5.95%
controls:0.75%
cases:3.49%
controls:3.06%
12
66
375
3804
11
25
376
3845
—
—
—
22
28
348
3716
11
98
304
3103
Laceration/cut
S18 [2002000983]
1.3e-01
4.2e-01
—
—
2.2e+00
1.3e+00
3.9e-01
cases:9.30%
controls:8.24%
cases:5.17%
controls:3.46%
—
—
—
—
cases:3.11%
controls:0.34%
cases:10.54%
controls:3.13%
cases:14.92%
controls:10.62%
36
319
351
3551
20
134
367
3736
—
—
12
13
374
3848
39
117
331
3627
47
340
268
2861
Thoracal spine MRI examination with high intensity magnet
NA2BG [2001307013]
—
—
1.0e+50
1.0e+50
—
—
3.5e+00
—
—
—
—
cases:1.81%
controls:0.00%
cases:2.33%
controls:0.00%
—
—
—
—
cases:4.76%
controls:0.16%
—
—
7
0
380
3870
9
0
378
3870
—
—
15
5
300
3196
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
1.4e+00
1.5e+00
—
—
—
2.0e+00
4.0e-01
cases:2.58%
controls:0.65%
cases:1.55%
controls:0.34%
—
—
—
—
—
—
cases:2.43%
controls:0.32%
cases:2.22%
controls:1.50%
10
25
377
3845
6
13
381
3857
—
—
—
9
12
361
3732
7
48
308
3153
One hour or less
ZXE00 [2001311394]
4.2e-01
2.4e-01
2.1e+00
—
2.2e+00
1.3e+00
6.2e-01
cases:9.82%
controls:6.69%
cases:2.07%
controls:1.63%
cases:1.29%
controls:0.16%
—
—
cases:1.55%
controls:0.18%
cases:4.32%
controls:1.23%
cases:8.25%
controls:4.62%
38
259
349
3611
8
63
379
3807
5
6
382
3864
—
6
7
380
3854
16
46
354
3698
26
148
289
3053
Right side
ZXA00 [2001311346]
2.4e-02
1.3e+00
—
1.0e+50
2.2e+00
1.1e+00
4.5e-01
cases:4.65%
controls:4.55%
cases:3.36%
controls:0.98%
—
—
cases:1.29%
controls:0.00%
cases:1.55%
controls:0.18%
cases:2.70%
controls:0.91%
cases:4.44%
controls:2.87%
18
176
369
3694
13
38
374
3832
—
5
0
382
3870
6
7
380
3854
10
34
360
3710
14
92
301
3109
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
2.5e-01
-4.2e-01
1.5e+00
—
1.5e+00
1.2e+00
6.8e-01
cases:7.75%
controls:6.12%
cases:2.33%
controls:3.49%
cases:1.55%
controls:0.36%
—
—
cases:3.11%
controls:0.73%
cases:10.27%
controls:3.18%
cases:17.14%
controls:9.47%
30
237
357
3633
9
135
378
3735
6
14
381
3856
—
12
28
374
3833
38
119
332
3625
54
303
261
2898
More than one and less than three hours
ZXE10 [2001311401]
4.5e-01
9.4e-01
—
1.0e+50
—
2.3e+00
1.1e+00
cases:8.53%
controls:5.61%
cases:4.13%
controls:1.65%
—
—
cases:4.91%
controls:0.00%
—
—
cases:7.03%
controls:0.77%
cases:9.21%
controls:3.22%
33
217
354
3653
16
64
371
3806
—
19
0
368
3870
—
26
29
344
3715
29
103
286
3098
codeine and paracetamol
N02AJ06 [1123647]
4.1e-01
9.1e-01
9.1e-01
—
1.5e+00
9.0e-01
3.5e-01
cases:18.86%
controls:13.39%
cases:13.44%
controls:5.89%
cases:3.10%
controls:1.27%
—
—
cases:4.92%
controls:1.14%
cases:12.43%
controls:5.48%
cases:18.41%
controls:13.75%
73
518
314
3352
52
228
335
3642
12
49
375
3821
—
19
44
367
3817
46
205
324
3539
58
440
257
2761
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
-1.7e-02
8.7e-01
—
—
—
1.9e+00
1.4e+00
cases:1.55%
controls:1.58%
cases:1.29%
controls:0.54%
—
—
—
—
—
—
cases:1.89%
controls:0.29%
cases:3.49%
controls:0.87%
6
61
381
3809
5
21
382
3849
—
—
—
7
11
363
3733
11
28
304
3173
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
3.8e-01
8.0e-01
—
—
2.1e+00
1.1e+00
2.8e-01
cases:5.17%
controls:3.59%
cases:3.88%
controls:1.78%
—
—
—
—
cases:2.07%
controls:0.26%
cases:4.86%
controls:1.60%
cases:4.76%
controls:3.66%
20
139
367
3731
15
69
372
3801
—
—
8
10
378
3851
18
60
352
3684
15
117
300
3084
ibuprofen
R02AX02 [1588667]
2.0e-01
6.1e-01
7.3e-01
—
1.5e+00
6.5e-01
4.6e-01
cases:36.18%
controls:31.76%
cases:23.77%
controls:14.50%
cases:4.91%
controls:2.43%
—
—
cases:7.77%
controls:1.86%
cases:22.16%
controls:12.98%
cases:41.90%
controls:31.24%
140
1229
247
2641
92
561
295
3309
19
94
368
3776
—
30
72
356
3789
82
486
288
3258
132
1000
183
2201
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
2.0e-01
6.1e-01
7.3e-01
—
1.5e+00
6.5e-01
4.6e-01
cases:36.18%
controls:31.76%
cases:23.77%
controls:14.50%
cases:4.91%
controls:2.43%
—
—
cases:7.77%
controls:1.86%
cases:22.16%
controls:12.98%
cases:41.90%
controls:31.24%
140
1229
247
2641
92
561
295
3309
19
94
368
3776
—
30
72
356
3789
82
486
288
3258
132
1000
183
2201
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
4.9e-02
4.0e-01
1.2e+00
—
1.2e+00
7.0e-01
3.4e-01
cases:16.80%
controls:16.12%
cases:12.66%
controls:8.86%
cases:3.88%
controls:1.19%
—
—
cases:4.92%
controls:1.55%
cases:16.22%
controls:8.79%
cases:28.89%
controls:22.46%
65
624
322
3246
49
343
338
3527
15
46
372
3824
—
19
60
367
3801
60
329
310
3415
91
719
224
2482
Endocrinology
46 [38004485]
8.2e-01
1.1e+00
1.5e+00
—
—
1.2e+00
5.3e-01
cases:6.20%
controls:2.82%
cases:4.65%
controls:1.63%
cases:1.55%
controls:0.34%
—
—
—
—
cases:5.41%
controls:1.76%
cases:6.35%
controls:3.84%
24
109
363
3761
18
63
369
3807
6
13
381
3857
—
—
20
66
350
3678
20
123
295
3078
Urology
34 [38004474]
4.3e-01
7.6e-01
—
—
-1.0e+50
1.7e+00
1.3e+00
cases:8.27%
controls:5.53%
cases:4.91%
controls:2.35%
—
—
—
—
cases:0.00%
controls:0.47%
cases:11.62%
controls:2.30%
cases:17.46%
controls:5.37%
32
214
355
3656
19
91
368
3779
—
—
0
18
386
3843
43
86
327
3658
55
172
260
3029
General anaesthesia
WX402 [2001310806]
5.2e-01
6.8e-01
—
1.0e+50
3.0e+00
1.1e+00
4.8e-01
cases:4.39%
controls:2.66%
cases:2.07%
controls:1.06%
—
—
cases:1.55%
controls:0.00%
cases:4.15%
controls:0.21%
cases:2.97%
controls:0.99%
cases:5.40%
controls:3.41%
17
103
370
3767
8
41
379
3829
—
6
0
381
3870
16
8
370
3853
11
37
359
3707
17
109
298
3092
Gas panel - Venous blood
24339-4 [3000991]
4.9e-01
1.2e+00
—
—
3.0e+00
1.4e+00
4.5e-01
cases:1.55%
controls:0.96%
cases:1.55%
controls:0.47%
—
—
—
—
cases:2.59%
controls:0.13%
cases:2.16%
controls:0.53%
cases:3.49%
controls:2.25%
6
37
381
3833
6
18
381
3852
—
—
10
5
376
3856
8
20
362
3724
11
72
304
3129
CBC panel - Blood by Automated count
58410-2 [40761511]
4.5e-02
4.0e-01
1.1e+00
—
1.5e+00
4.7e-01
1.4e-01
cases:32.04%
controls:31.06%
cases:28.17%
controls:20.83%
cases:10.59%
controls:3.93%
—
—
cases:15.03%
controls:3.91%
cases:30.54%
controls:21.61%
cases:43.81%
controls:40.36%
124
1202
263
2668
109
806
278
3064
41
152
346
3718
—
58
151
328
3710
113
809
257
2935
138
1292
177
1909
Internal Medicine
11 [38004456]
1.6e-01
5.1e-01
1.3e+00
—
1.1e+00
5.5e-01
3.8e-01
cases:25.84%
controls:22.82%
cases:14.21%
controls:9.07%
cases:6.20%
controls:1.81%
—
—
cases:4.15%
controls:1.37%
cases:14.86%
controls:9.19%
cases:27.94%
controls:20.99%
100
883
287
2987
55
351
332
3519
24
70
363
3800
—
16
53
370
3808
55
344
315
3400
88
672
227
2529
lactulose; oral
A06AD11 [21600571]
7.1e-01
6.2e-01
—
—
—
1.8e+00
1.2e+00
cases:2.84%
controls:1.42%
cases:1.81%
controls:0.98%
—
—
—
—
—
—
cases:4.32%
controls:0.75%
cases:6.67%
controls:2.19%
11
55
376
3815
7
38
380
3832
—
—
—
16
28
354
3716
21
70
294
3131
Physiotherapist
Z3226 [2001311560]
8.9e-01
1.2e+00
—
1.0e+50
—
2.0e+00
1.1e+00
cases:5.17%
controls:2.20%
cases:2.58%
controls:0.83%
—
—
cases:2.58%
controls:0.00%
—
—
cases:3.51%
controls:0.48%
cases:3.81%
controls:1.31%
20
85
367
3785
10
32
377
3838
—
10
0
377
3870
—
13
18
357
3726
12
42
303
3159
Physiologic investigation of micturition
XKD06 [2001306098]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.81%
controls:0.22%
—
—
—
—
—
—
12
7
303
3194
More than three and less than five hours
ZXE20 [2001311408]
7.6e-01
1.3e+00
—
1.0e+50
—
2.8e+00
1.2e+00
cases:3.62%
controls:1.73%
cases:1.81%
controls:0.49%
—
—
cases:4.39%
controls:0.00%
—
—
cases:2.70%
controls:0.16%
cases:3.17%
controls:0.94%
14
67
373
3803
7
19
380
3851
—
17
0
370
3870
—
10
6
360
3738
10
30
305
3171
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
1.7e-01
2.7e-01
9.3e-01
—
1.4e+00
9.2e-01
5.5e-01
cases:17.57%
controls:15.22%
cases:10.08%
controls:7.91%
cases:2.84%
controls:1.14%
—
—
cases:5.96%
controls:1.61%
cases:17.57%
controls:7.83%
cases:31.43%
controls:20.99%
68
589
319
3281
39
306
348
3564
11
44
376
3826
—
23
62
363
3799
65
293
305
3451
99
672
216
2529
omeprazole; oral, parenteral
A02BC01 [21600096]
6.5e-01
7.7e-01
—
—
1.9e+00
9.1e-01
5.7e-01
cases:8.27%
controls:4.50%
cases:4.39%
controls:2.09%
—
—
—
—
cases:2.33%
controls:0.36%
cases:6.22%
controls:2.59%
cases:7.62%
controls:4.47%
32
174
355
3696
17
81
370
3789
—
—
9
14
377
3847
23
97
347
3647
24
143
291
3058
12 lead EKG panel
34534-8 [3044889]
1.1e-01
3.6e-01
1.1e+00
—
1.6e+00
4.1e-01
1.6e-01
cases:19.90%
controls:18.24%
cases:13.18%
controls:9.59%
cases:4.39%
controls:1.45%
—
—
cases:5.70%
controls:1.17%
cases:13.51%
controls:9.38%
cases:27.62%
controls:24.49%
77
706
310
3164
51
371
336
3499
17
56
370
3814
—
22
45
364
3816
50
351
320
3393
87
784
228
2417
Lumbar spine extensive MRI examination with high intensity magnet
NA3CG [2001307039]
—
—
—
1.0e+50
—
—
2.7e+00
—
—
—
—
—
—
cases:2.07%
controls:0.00%
—
—
—
—
cases:2.86%
controls:0.19%
—
—
—
8
0
379
3870
—
—
9
6
306
3195
esomeprazole; oral, parenteral
A02BC05 [21600100]
3.3e-01
5.1e-01
5.4e-01
—
1.4e+00
6.9e-01
7.0e-01
cases:12.92%
controls:9.61%
cases:8.01%
controls:4.99%
cases:2.33%
controls:1.37%
—
—
cases:3.63%
controls:0.96%
cases:10.54%
controls:5.58%
cases:16.83%
controls:9.12%
50
372
337
3498
31
193
356
3677
9
53
378
3817
—
14
37
372
3824
39
209
331
3535
53
292
262
2909
Potassium [Moles/volume] in Arterial blood
32713-0 [3043409]
-1.0e+50
—
—
—
—
2.7e+00
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
cases:2.43%
controls:0.16%
—
—
0
22
387
3848
—
—
—
—
9
6
361
3738
—
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
4.5e-01
6.9e-01
1.6e+00
—
1.1e+00
2.8e-01
2.8e-01
cases:20.41%
controls:14.03%
cases:9.04%
controls:4.75%
cases:3.10%
controls:0.65%
—
—
cases:1.30%
controls:0.44%
cases:6.22%
controls:4.78%
cases:17.14%
controls:13.56%
79
543
308
3327
35
184
352
3686
12
25
375
3845
—
5
17
381
3844
23
179
347
3565
54
434
261
2767
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
9.3e-01
1.1e+00
—
—
2.7e+00
1.2e+00
4.5e-01
cases:2.07%
controls:0.83%
cases:1.81%
controls:0.59%
—
—
—
—
cases:2.33%
controls:0.16%
cases:1.62%
controls:0.48%
cases:3.49%
controls:2.25%
8
32
379
3838
7
23
380
3847
—
—
9
6
377
3855
6
18
364
3726
11
72
304
3129
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
1.2e+00
1.7e+00
—
—
—
2.7e+00
9.2e-01
cases:3.10%
controls:0.98%
cases:1.81%
controls:0.34%
—
—
—
—
—
—
cases:2.70%
controls:0.19%
cases:2.54%
controls:1.03%
12
38
375
3832
7
13
380
3857
—
—
—
10
7
360
3737
8
33
307
3168
Back symptom/complaint
L02 [2002000627]
—
—
—
—
—
2.6e+00
9.5e-01
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.16%
cases:2.86%
controls:1.12%
—
—
—
—
—
8
6
362
3738
9
36
306
3165
methylprednisolone; oral, parenteral
H02AB04 [21602732]
7.0e-01
1.2e+00
—
—
—
1.5e+00
1.1e+00
cases:3.88%
controls:1.96%
cases:1.81%
controls:0.54%
—
—
—
—
—
—
cases:2.70%
controls:0.61%
cases:5.08%
controls:1.75%
15
76
372
3794
7
21
380
3849
—
—
—
10
23
360
3721
16
56
299
3145
Lactate [Moles/volume] in Arterial blood
2518-9 [3018405]
-1.0e+50
—
—
—
—
2.6e+00
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
cases:2.43%
controls:0.19%
—
—
0
23
387
3847
—
—
—
—
9
7
361
3737
—
Upper gastrointestinal surgery
106 [44777669]
4.5e-01
4.6e-01
—
—
1.7e+00
8.4e-01
4.4e-01
cases:13.44%
controls:9.02%
cases:5.43%
controls:3.49%
—
—
—
—
cases:2.33%
controls:0.41%
cases:6.49%
controls:2.91%
cases:15.24%
controls:10.40%
52
349
335
3521
21
135
366
3735
—
—
9
16
377
3845
24
109
346
3635
48
333
267
2868
Limited function/disability (L)
L28 [2002000647]
5.5e-01
1.0e+00
1.3e+00
—
1.4e+00
1.6e+00
6.1e-01
cases:4.13%
controls:2.43%
cases:3.88%
controls:1.45%
cases:1.29%
controls:0.36%
—
—
cases:1.30%
controls:0.34%
cases:7.03%
controls:1.58%
cases:7.30%
controls:4.09%
16
94
371
3776
15
56
372
3814
5
14
382
3856
—
5
13
381
3848
26
59
344
3685
23
131
292
3070
Urinary tract ultrasound examination
KH1AE [2001306329]
—
-1.0e+50
—
—
—
—
2.6e+00
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:3.49%
controls:0.28%
—
0
9
387
3861
—
—
—
—
11
9
304
3192
Abdominal ultrasound examination
JN3AE [2001305555]
9.6e-01
2.5e+00
—
—
-1.0e+50
—
6.7e-01
cases:3.62%
controls:1.42%
cases:2.84%
controls:0.23%
—
—
—
—
cases:0.00%
controls:0.13%
—
—
cases:2.54%
controls:1.31%
14
55
373
3815
11
9
376
3861
—
—
0
5
386
3856
—
8
42
307
3159
baclofen; oral, parenteral
M03BX01 [21604115]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.90%
controls:0.16%
—
—
—
—
—
—
6
5
309
3196
Lower urinary tract urodynamic studies
252896003 [4099392]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.90%
controls:0.16%
—
—
—
—
—
—
6
5
309
3196
Care involving use of rehabilitation procedure, unspecified
Z50.9 [45595525]
—
—
—
—
—
2.5e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.13%
cases:1.90%
controls:0.47%
—
—
—
—
—
6
5
364
3739
6
15
309
3186
Radiotherapy with large shaped fields - isocentric therapy
ZX012 [2001311468]
7.0e-01
—
—
—
—
2.5e+00
—
cases:1.29%
controls:0.65%
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.13%
—
—
5
25
382
3845
—
—
—
—
6
5
364
3739
—
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
—
1.5e+00
—
—
—
2.5e+00
3.0e-01
—
—
cases:1.55%
controls:0.36%
—
—
—
—
—
—
cases:3.78%
controls:0.32%
cases:2.22%
controls:1.66%
—
6
14
381
3856
—
—
—
14
12
356
3732
7
53
308
3148
Medical doctor
Z2221 [2001311556]
2.4e-01
1.4e+00
2.1e+00
—
—
1.1e+00
8.7e-01
cases:6.72%
controls:5.37%
cases:4.65%
controls:1.24%
cases:1.29%
controls:0.16%
—
—
—
—
cases:4.05%
controls:1.34%
cases:5.40%
controls:2.34%
26
208
361
3662
18
48
369
3822
5
6
382
3864
—
—
15
50
355
3694
17
75
298
3126
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
2.3e-02
—
-1.0e+50
—
2.5e+00
1.0e+00
9.3e-01
cases:2.33%
controls:2.27%
—
—
cases:0.00%
controls:0.13%
—
—
cases:1.81%
controls:0.16%
cases:2.43%
controls:0.91%
cases:4.76%
controls:1.94%
9
88
378
3782
—
0
5
387
3865
—
7
6
379
3855
9
34
361
3710
15
62
300
3139
Bacteria identified in Urine by Culture
630-4 [3026008]
-4.1e-02
1.3e-01
—
—
1.3e+00
1.1e+00
3.5e-01
cases:5.94%
controls:6.18%
cases:3.36%
controls:2.97%
—
—
—
—
cases:3.11%
controls:0.83%
cases:9.46%
controls:3.34%
cases:13.65%
controls:10.03%
23
239
364
3631
13
115
374
3755
—
—
12
32
374
3829
35
125
335
3619
43
321
272
2880
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
1.5e-01
9.1e-01
9.2e-01
—
1.1e+00
2.8e-01
4.4e-01
cases:20.93%
controls:18.58%
cases:22.48%
controls:10.47%
cases:3.88%
controls:1.58%
—
—
cases:4.15%
controls:1.42%
cases:11.89%
controls:9.29%
cases:33.33%
controls:24.37%
81
719
306
3151
87
405
300
3465
15
61
372
3809
—
16
55
370
3806
44
348
326
3396
105
780
210
2421
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.9e-02
5.0e-01
8.4e-01
—
1.1e+00
4.7e-01
3.4e-01
cases:20.16%
controls:19.22%
cases:19.12%
controls:12.58%
cases:5.43%
controls:2.43%
—
—
cases:7.25%
controls:2.54%
cases:17.84%
controls:11.91%
cases:33.02%
controls:26.05%
78
744
309
3126
74
487
313
3383
21
94
366
3776
—
28
98
358
3763
66
446
304
3298
104
834
211
2367
Pain in thoracic spine
M54.6 [45606247]
1.3e+00
2.4e+00
—
—
—
—
8.6e-01
cases:2.07%
controls:0.57%
cases:2.58%
controls:0.23%
—
—
—
—
—
—
—
—
cases:1.90%
controls:0.81%
8
22
379
3848
10
9
377
3861
—
—
—
—
6
26
309
3175
Cervical spine MRI examination with high intensity magnet
NA1BG [2001306990]
8.4e-01
—
—
1.0e+50
—
—
2.4e+00
cases:1.55%
controls:0.67%
—
—
—
—
cases:1.29%
controls:0.00%
—
—
—
—
cases:5.08%
controls:0.47%
6
26
381
3844
—
—
5
0
382
3870
—
—
16
15
299
3186
Lumbago with sciatica
M54.4 [45553205]
6.6e-01
1.5e+00
2.1e+00
—
—
1.6e-01
8.8e-01
cases:3.88%
controls:2.04%
cases:3.88%
controls:0.85%
cases:1.29%
controls:0.16%
—
—
—
—
cases:1.35%
controls:1.15%
cases:6.98%
controls:3.03%
15
79
372
3791
15
33
372
3837
5
6
382
3864
—
—
5
43
365
3701
22
97
293
3104
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
2.2e-01
—
—
—
1.5e+00
1.4e+00
9.8e-01
cases:4.39%
controls:3.57%
—
—
—
—
—
—
cases:1.30%
controls:0.28%
cases:5.41%
controls:1.39%
cases:10.48%
controls:4.22%
17
138
370
3732
—
—
—
5
11
381
3850
20
52
350
3692
33
135
282
3066
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
—
1.5e+00
—
—
—
2.3e+00
3.2e-01
—
—
cases:1.55%
controls:0.36%
—
—
—
—
—
—
cases:3.51%
controls:0.35%
cases:2.22%
controls:1.62%
—
6
14
381
3856
—
—
—
13
13
357
3731
7
52
308
3149
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
—
1.6e+00
—
—
—
2.3e+00
3.2e-01
—
—
cases:1.55%
controls:0.31%
—
—
—
—
—
—
cases:3.24%
controls:0.32%
cases:2.22%
controls:1.62%
—
6
12
381
3858
—
—
—
12
12
358
3732
7
52
308
3149
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
9.1e-02
8.7e-01
8.2e-01
—
1.5e+00
4.5e-01
5.4e-02
cases:14.47%
controls:13.39%
cases:12.92%
controls:5.87%
cases:1.81%
controls:0.80%
—
—
cases:3.63%
controls:0.85%
cases:9.19%
controls:6.04%
cases:20.00%
controls:19.15%
56
518
331
3352
50
227
337
3643
7
31
380
3839
—
14
33
372
3828
34
226
336
3518
63
613
252
2588
Occupational therapy
R4120 [2001310234]
7.7e-01
—
—
—
—
2.3e+00
—
cases:1.55%
controls:0.72%
—
—
—
—
—
—
—
—
cases:2.70%
controls:0.27%
—
—
6
28
381
3842
—
—
—
—
10
10
360
3734
—
Other physical therapy
Z50.1 [45600331]
—
—
—
—
—
2.3e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:1.89%
controls:0.19%
cases:2.86%
controls:0.72%
—
—
—
—
—
7
7
363
3737
9
23
306
3178
Flexible sigmoidoscopy with biopsy
UJF45 [2001305031]
5.2e-01
—
—
—
—
2.3e+00
—
cases:1.81%
controls:1.09%
—
—
—
—
—
—
—
—
cases:1.35%
controls:0.13%
—
—
7
42
380
3828
—
—
—
—
5
5
365
3739
—
Radical radiotherapy
WF002 [2001310701]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:1.35%
controls:0.13%
—
—
—
—
—
—
—
5
5
365
3739
—
Leg/thigh symptom/complaint
L14 [2002000638]
-4.0e-02
2.3e+00
—
—
—
-1.0e+50
2.9e-01
cases:1.29%
controls:1.34%
cases:1.81%
controls:0.18%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:1.59%
controls:1.19%
5
52
382
3818
7
7
380
3863
—
—
—
0
14
370
3730
5
38
310
3163
Gas and Carbon monoxide and Electrolytes panel - Arterial blood
93685-6 [1001509]
2.3e+00
—
—
—
1.0e+50
—
-1.0e+50
cases:1.55%
controls:0.16%
—
—
—
—
—
—
cases:2.33%
controls:0.00%
—
—
cases:0.00%
controls:0.16%
6
6
381
3864
—
—
—
9
0
377
3861
—
0
5
315
3196
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1.8e-01
7.1e-01
1.0e+00
—
1.6e+00
5.4e-01
2.8e-01
cases:10.08%
controls:8.58%
cases:9.56%
controls:4.96%
cases:2.58%
controls:0.93%
—
—
cases:3.37%
controls:0.70%
cases:7.57%
controls:4.54%
cases:16.51%
controls:13.00%
39
332
348
3538
37
192
350
3678
10
36
377
3834
—
13
27
373
3834
28
170
342
3574
52
416
263
2785
pantoprazole; oral, parenteral
A02BC02 [21600097]
3.1e-01
5.2e-01
7.7e-01
—
1.1e+00
5.9e-01
3.3e-01
cases:24.03%
controls:18.86%
cases:16.80%
controls:10.75%
cases:5.43%
controls:2.58%
—
—
cases:6.99%
controls:2.38%
cases:18.11%
controls:10.87%
cases:27.62%
controls:21.56%
93
730
294
3140
65
416
322
3454
21
100
366
3770
—
27
92
359
3769
67
407
303
3337
87
690
228
2511
Pulmonary Disease
29 [38004472]
1.3e-01
4.0e-01
1.4e+00
—
9.3e-01
7.9e-01
4.7e-01
cases:10.59%
controls:9.43%
cases:6.72%
controls:4.63%
cases:3.10%
controls:0.78%
—
—
cases:2.07%
controls:0.83%
cases:8.92%
controls:4.27%
cases:15.24%
controls:10.06%
41
365
346
3505
26
179
361
3691
12
30
375
3840
—
8
32
378
3829
33
160
337
3584
48
322
267
2879
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
1.1e-01
2.6e-01
1.1e+00
—
1.5e+00
6.8e-01
1.9e-01
cases:9.56%
controls:8.63%
cases:7.24%
controls:5.66%
cases:2.33%
controls:0.78%
—
—
cases:3.89%
controls:0.88%
cases:11.35%
controls:6.12%
cases:19.37%
controls:16.56%
37
334
350
3536
28
219
359
3651
9
30
378
3840
—
15
34
371
3827
42
229
328
3515
61
530
254
2671
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
5.2e-02
2.8e-01
1.1e+00
—
1.5e+00
6.7e-01
2.4e-01
cases:9.56%
controls:9.12%
cases:7.49%
controls:5.79%
cases:2.33%
controls:0.80%
—
—
cases:3.89%
controls:0.88%
cases:11.62%
controls:6.30%
cases:20.63%
controls:16.93%
37
353
350
3517
29
224
358
3646
9
31
378
3839
—
15
34
371
3827
43
236
327
3508
65
542
250
2659
Geriatric Medicine
38 [38004478]
-1.0e+50
2.2e+00
—
—
—
-1.0e+50
2.7e-01
cases:0.00%
controls:0.62%
cases:1.81%
controls:0.21%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:1.59%
controls:1.22%
0
24
387
3846
7
8
380
3862
—
—
—
0
13
370
3731
5
39
310
3162
Body temperature
8310-5 [3020891]
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.97%
controls:0.35%
—
—
—
—
—
—
—
11
13
359
3731
—
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
—
1.3e+00
—
—
1.0e+50
2.2e+00
—
—
—
cases:1.29%
controls:0.36%
—
—
—
—
cases:1.55%
controls:0.00%
cases:4.05%
controls:0.48%
—
—
—
5
14
382
3856
—
—
6
0
380
3861
15
18
355
3726
—
Monitoring the use of the aid
R5140 [2001310249]
1.1e+00
1.4e+00
—
—
—
8.4e-01
1.1e+00
cases:3.36%
controls:1.16%
cases:1.29%
controls:0.34%
—
—
—
—
—
—
cases:1.35%
controls:0.59%
cases:5.08%
controls:1.78%
13
45
374
3825
5
13
382
3857
—
—
—
5
22
365
3722
16
57
299
3144
Cathetrisation of vein
TPH04 [2001309597]
4.0e-01
1.5e-01
2.2e+00
—
1.9e+00
1.1e+00
1.4e-01
cases:4.65%
controls:3.18%
cases:1.29%
controls:1.11%
cases:1.55%
controls:0.18%
—
—
cases:1.55%
controls:0.23%
cases:2.70%
controls:0.91%
cases:4.13%
controls:3.59%
18
123
369
3747
5
43
382
3827
6
7
381
3863
—
6
9
380
3852
10
34
360
3710
13
115
302
3086
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
-1.0e-01
5.2e-01
7.3e-01
—
1.3e+00
7.8e-01
2.0e-01
cases:9.82%
controls:10.75%
cases:9.82%
controls:6.07%
cases:2.84%
controls:1.40%
—
—
cases:4.40%
controls:1.22%
cases:11.62%
controls:5.66%
cases:19.05%
controls:16.18%
38
416
349
3454
38
235
349
3635
11
54
376
3816
—
17
47
369
3814
43
212
327
3532
60
518
255
2683
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
1.3e-01
3.3e-01
1.2e+00
—
1.5e+00
6.3e-01
1.9e-01
cases:9.82%
controls:8.76%
cases:7.75%
controls:5.71%
cases:2.58%
controls:0.80%
—
—
cases:3.89%
controls:0.93%
cases:11.08%
controls:6.22%
cases:19.68%
controls:16.87%
38
339
349
3531
30
221
357
3649
10
31
377
3839
—
15
36
371
3825
41
233
329
3511
62
540
253
2661
Otolaryngology
4 [38004449]
5.2e-01
4.1e-01
5.5e-01
—
7.3e-01
9.2e-01
6.4e-01
cases:17.05%
controls:10.90%
cases:6.72%
controls:4.55%
cases:1.55%
controls:0.90%
—
—
cases:1.81%
controls:0.88%
cases:9.46%
controls:3.98%
cases:19.37%
controls:11.22%
66
422
321
3448
26
176
361
3694
6
35
381
3835
—
7
34
379
3827
35
149
335
3595
61
359
254
2842
Emergency Medicine
93 [38004510]
3.1e-01
6.6e-01
1.4e+00
—
1.1e+00
4.8e-01
2.8e-01
cases:16.28%
controls:12.51%
cases:12.66%
controls:6.95%
cases:3.62%
controls:0.90%
—
—
cases:3.37%
controls:1.19%
cases:12.97%
controls:8.47%
cases:26.03%
controls:21.09%
63
484
324
3386
49
269
338
3601
14
35
373
3835
—
13
46
373
3815
48
317
322
3427
82
675
233
2526
Thorax CT examination
GD1AD [2001303618]
2.1e+00
—
—
—
—
—
—
cases:1.81%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
380
3861
—
—
—
—
—
—
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.7e-02
7.4e-02
7.9e-01
—
1.3e+00
2.4e-01
-2.5e-02
cases:27.13%
controls:26.80%
cases:23.26%
controls:21.96%
cases:10.59%
controls:5.12%
—
—
cases:15.28%
controls:4.90%
cases:28.38%
controls:23.85%
cases:38.10%
controls:38.68%
105
1037
282
2833
90
850
297
3020
41
198
346
3672
—
59
189
327
3672
105
893
265
2851
120
1238
195
1963
Intraoperative use of conventional X-ray imaging
ZXM10 [2001311446]
—
—
—
1.0e+50
1.0e+50
2.0e+00
1.6e+00
—
—
—
—
—
—
cases:2.33%
controls:0.00%
cases:3.63%
controls:0.00%
cases:1.62%
controls:0.21%
cases:2.22%
controls:0.47%
—
—
—
9
0
378
3870
14
0
372
3861
6
8
364
3736
7
15
308
3186
Benign tumor of the meninges at the base of the brain
D32.02 [2000501309]
2.0e+00
—
—
—
—
—
—
cases:1.55%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
381
3862
—
—
—
—
—
—
Repair work or maintenance done on the aid
R5130 [2001310248]
2.0e+00
—
—
—
—
—
1.3e+00
cases:1.55%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
cases:2.22%
controls:0.59%
6
8
381
3862
—
—
—
—
—
7
19
308
3182
carisoprodol; oral
M03BA02 [21604094]
2.0e+00
—
—
—
—
—
—
cases:1.55%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
381
3862
—
—
—
—
—
—
Thorax X-ray examination
GD1AA [2001303617]
1.9e-01
6.1e-01
1.5e+00
—
2.0e+00
3.7e-01
4.3e-01
cases:10.59%
controls:8.89%
cases:6.72%
controls:3.77%
cases:1.81%
controls:0.41%
—
—
cases:2.85%
controls:0.39%
cases:5.14%
controls:3.61%
cases:14.29%
controls:9.75%
41
344
346
3526
26
146
361
3724
7
16
380
3854
—
11
15
375
3846
19
135
351
3609
45
312
270
2889
Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 [3016888]
5.9e-01
2.0e+00
—
—
—
—
5.7e-01
cases:1.81%
controls:1.01%
cases:2.07%
controls:0.28%
—
—
—
—
—
—
—
—
cases:1.59%
controls:0.91%
7
39
380
3831
8
11
379
3859
—
—
—
—
5
29
310
3172
Emergency Room and Inpatient Visit
ERIP [262]
1.5e-01
4.7e-01
—
1.0e+50
2.0e+00
7.3e-01
1.7e-01
cases:4.91%
controls:4.24%
cases:4.13%
controls:2.64%
—
—
cases:2.33%
controls:0.00%
cases:2.59%
controls:0.36%
cases:5.68%
controls:2.83%
cases:10.16%
controls:8.68%
19
164
368
3706
16
102
371
3768
—
9
0
378
3870
10
14
376
3847
21
106
349
3638
32
278
283
2923
oxcarbazepine; oral
N03AF02 [21604418]
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
cases:1.89%
controls:0.27%
—
—
—
—
—
—
—
7
10
363
3734
—
Bacteria [Presence] in Urine
87829-8 [36304419]
2.7e-01
-5.7e-01
1.7e+00
—
1.3e+00
1.2e+00
7.3e-01
cases:5.68%
controls:4.39%
cases:1.55%
controls:2.71%
cases:1.55%
controls:0.28%
—
—
cases:2.07%
controls:0.60%
cases:8.38%
controls:2.59%
cases:13.65%
controls:7.06%
22
170
365
3700
6
105
381
3765
6
11
381
3859
—
8
23
378
3838
31
97
339
3647
43
226
272
2975
INR in Blood by Coagulation assay
34714-6 [3032080]
2.3e-01
2.5e-01
6.4e-01
—
1.1e+00
8.9e-01
1.8e-01
cases:12.40%
controls:10.16%
cases:6.98%
controls:5.53%
cases:3.62%
controls:1.94%
—
—
cases:5.70%
controls:2.05%
cases:12.43%
controls:5.50%
cases:16.19%
controls:13.90%
48
393
339
3477
27
214
360
3656
14
75
373
3795
—
22
79
364
3782
46
206
324
3538
51
445
264
2756
Pain in limb
M79.6 [45587063]
2.9e-01
1.3e+00
—
—
—
1.7e-01
6.2e-01
cases:9.04%
controls:6.93%
cases:8.27%
controls:2.40%
—
—
—
—
—
—
cases:2.97%
controls:2.51%
cases:14.92%
controls:8.59%
35
268
352
3602
32
93
355
3777
—
—
—
11
94
359
3650
47
275
268
2926
Person consulting for explanation of investigation findings
Z71.2 [45552100]
3.0e-01
1.1e+00
—
—
—
1.3e-01
7.9e-01
cases:5.94%
controls:4.47%
cases:5.17%
controls:1.73%
—
—
—
—
—
—
cases:2.43%
controls:2.14%
cases:12.06%
controls:5.87%
23
173
364
3697
20
67
367
3803
—
—
—
9
80
361
3664
38
188
277
3013
Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 [3008230]
4.7e-01
1.9e+00
—
—
—
—
5.9e-01
cases:1.81%
controls:1.14%
cases:2.07%
controls:0.31%
—
—
—
—
—
—
—
—
cases:1.90%
controls:1.06%
7
44
380
3826
8
12
379
3858
—
—
—
—
6
34
309
3167
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
1.8e-01
-5.1e-01
1.5e+00
—
1.1e+00
1.2e+00
7.0e-01
cases:6.46%
controls:5.48%
cases:2.07%
controls:3.39%
cases:1.55%
controls:0.36%
—
—
cases:2.07%
controls:0.73%
cases:9.73%
controls:3.10%
cases:15.56%
controls:8.40%
25
212
362
3658
8
131
379
3739
6
14
381
3856
—
8
28
378
3833
36
116
334
3628
49
269
266
2932
Oxygen saturation in Arterial blood
2708-6 [3016502]
1.5e-01
1.4e+00
—
—
—
1.9e+00
2.1e-01
cases:1.55%
controls:1.34%
cases:2.07%
controls:0.54%
—
—
—
—
—
—
cases:4.32%
controls:0.67%
cases:3.17%
controls:2.59%
6
52
381
3818
8
21
379
3849
—
—
—
16
25
354
3719
10
83
305
3118
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
2.0e-02
1.4e+00
—
—
—
1.9e+00
2.5e-01
cases:1.29%
controls:1.27%
cases:1.81%
controls:0.47%
—
—
—
—
—
—
cases:4.32%
controls:0.67%
cases:3.17%
controls:2.50%
5
49
382
3821
7
18
380
3852
—
—
—
16
25
354
3719
10
80
305
3121
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
2.5e-01
-5.3e-01
1.7e+00
—
1.3e+00
1.2e+00
7.3e-01
cases:5.94%
controls:4.68%
cases:1.81%
controls:3.02%
cases:1.55%
controls:0.28%
—
—
cases:2.33%
controls:0.65%
cases:8.38%
controls:2.75%
cases:14.29%
controls:7.44%
23
181
364
3689
7
117
380
3753
6
11
381
3859
—
9
25
377
3836
31
103
339
3641
45
238
270
2963
Perimetry
XCK00 [2001301380]
6.3e-01
—
—
—
—
1.9e+00
1.3e+00
cases:2.07%
controls:1.11%
—
—
—
—
—
—
—
—
cases:1.89%
controls:0.29%
cases:2.54%
controls:0.69%
8
43
379
3827
—
—
—
—
7
11
363
3733
8
22
307
3179
Infection following a procedure, not elsewhere classified
T81.4 [45575538]
—
—
—
—
—
1.9e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:2.70%
controls:0.43%
cases:2.54%
controls:0.75%
—
—
—
—
—
10
16
360
3728
8
24
307
3177
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
-2.3e-01
0.0e+00
1.2e+00
—
1.8e+00
2.1e-01
-1.2e-01
cases:3.10%
controls:3.88%
cases:2.58%
controls:2.58%
cases:1.29%
controls:0.39%
—
—
cases:2.07%
controls:0.34%
cases:3.78%
controls:3.10%
cases:7.94%
controls:8.84%
12
150
375
3720
10
100
377
3770
5
15
382
3855
—
8
13
378
3848
14
116
356
3628
25
283
290
2918
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
3.9e-01
5.5e-01
1.4e+00
—
1.8e+00
7.1e-01
3.1e-01
cases:5.43%
controls:3.75%
cases:4.65%
controls:2.74%
cases:1.29%
controls:0.31%
—
—
cases:2.07%
controls:0.34%
cases:5.68%
controls:2.88%
cases:10.48%
controls:7.87%
21
145
366
3725
18
106
369
3764
5
12
382
3858
—
8
13
378
3848
21
108
349
3636
33
252
282
2949
Dysphagia
R13 [45573013]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:0.75%
—
—
—
—
—
—
14
24
301
3177
enoxaparin; parenteral
B01AB05 [21600976]
-6.2e-02
2.0e-01
-1.0e+50
—
1.8e+00
5.5e-01
5.5e-01
cases:5.17%
controls:5.48%
cases:2.07%
controls:1.71%
cases:0.00%
controls:0.28%
—
—
cases:2.33%
controls:0.39%
cases:2.43%
controls:1.42%
cases:7.94%
controls:4.72%
20
212
367
3658
8
66
379
3804
0
11
387
3859
—
9
15
377
3846
9
53
361
3691
25
151
290
3050
Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2868-8 [3005229]
6.7e-01
1.8e+00
—
—
—
—
4.3e-01
cases:1.55%
controls:0.80%
cases:1.81%
controls:0.31%
—
—
—
—
—
—
—
—
cases:1.90%
controls:1.25%
6
31
381
3839
7
12
380
3858
—
—
—
—
6
40
309
3161
Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]
6.7e-01
1.8e+00
—
—
—
—
4.7e-01
cases:1.55%
controls:0.80%
cases:1.81%
controls:0.31%
—
—
—
—
—
—
—
—
cases:1.59%
controls:1.00%
6
31
381
3839
7
12
380
3858
—
—
—
—
5
32
310
3169
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]
6.7e-01
1.8e+00
—
—
—
—
4.3e-01
cases:1.55%
controls:0.80%
cases:1.81%
controls:0.31%
—
—
—
—
—
—
—
—
cases:1.90%
controls:1.25%
6
31
381
3839
7
12
380
3858
—
—
—
—
6
40
309
3161
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]
6.7e-01
1.8e+00
—
—
—
—
4.3e-01
cases:1.55%
controls:0.80%
cases:1.81%
controls:0.31%
—
—
—
—
—
—
—
—
cases:1.90%
controls:1.25%
6
31
381
3839
7
12
380
3858
—
—
—
—
6
40
309
3161
Asthma, unspecified
J45.9 [45562456]
0.0e+00
3.2e-01
—
1.0e+50
1.8e+00
7.9e-01
5.4e-01
cases:3.62%
controls:3.62%
cases:1.81%
controls:1.32%
—
—
cases:1.29%
controls:0.00%
cases:2.07%
controls:0.36%
cases:3.24%
controls:1.50%
cases:6.67%
controls:4.00%
14
140
373
3730
7
51
380
3819
—
5
0
382
3870
8
14
378
3847
12
56
358
3688
21
128
294
3073
Extensive body CT
JN4BD [2001310899]
1.7e-01
1.8e+00
—
—
—
—
8.2e-01
cases:1.81%
controls:1.52%
cases:2.07%
controls:0.36%
—
—
—
—
—
—
—
—
cases:1.90%
controls:0.84%
7
59
380
3811
8
14
379
3856
—
—
—
—
6
27
309
3174
Leukocytes [#/volume] in Urine
30405-5 [3018095]
2.3e-01
-2.0e-01
1.5e+00
—
1.2e+00
1.1e+00
6.4e-01
cases:7.49%
controls:6.05%
cases:3.36%
controls:4.08%
cases:2.07%
controls:0.49%
—
—
cases:2.59%
controls:0.83%
cases:10.81%
controls:3.87%
cases:17.78%
controls:10.28%
29
234
358
3636
13
158
374
3712
8
19
379
3851
—
10
32
376
3829
40
145
330
3599
56
329
259
2872
Sensorineural hearing loss, bilateral
H90.3 [45576850]
8.9e-01
7.3e-01
—
—
—
6.3e-01
8.5e-01
cases:5.94%
controls:2.53%
cases:2.84%
controls:1.40%
—
—
—
—
—
—
cases:2.43%
controls:1.31%
cases:8.25%
controls:3.72%
23
98
364
3772
11
54
376
3816
—
—
—
9
49
361
3695
26
119
289
3082
Gas panel - Arterial blood
24336-0 [3019060]
—
1.5e+00
—
—
1.0e+50
1.7e+00
2.9e-01
—
—
cases:1.55%
controls:0.36%
—
—
—
—
cases:1.81%
controls:0.00%
cases:2.70%
controls:0.51%
cases:1.90%
controls:1.44%
—
6
14
381
3856
—
—
7
0
379
3861
10
19
360
3725
6
46
309
3155
Disease/condition unspecnature/site
A99 [2002000232]
5.2e-01
1.7e+00
—
—
—
—
3.1e-01
cases:1.55%
controls:0.93%
cases:2.07%
controls:0.39%
—
—
—
—
—
—
—
—
cases:1.90%
controls:1.41%
6
36
381
3834
8
15
379
3855
—
—
—
—
6
45
309
3156
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
4.1e-02
6.2e-01
9.7e-01
—
1.7e+00
7.5e-01
3.1e-01
cases:6.98%
controls:6.72%
cases:5.94%
controls:3.28%
cases:1.55%
controls:0.59%
—
—
cases:2.59%
controls:0.49%
cases:6.22%
controls:3.04%
cases:11.75%
controls:8.87%
27
260
360
3610
23
127
364
3743
6
23
381
3847
—
10
19
376
3842
23
114
347
3630
37
284
278
2917
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
6.9e-01
1.7e+00
—
—
—
1.2e+00
7.7e-01
cases:2.84%
controls:1.45%
cases:2.84%
controls:0.54%
—
—
—
—
—
—
cases:1.89%
controls:0.56%
cases:3.49%
controls:1.66%
11
56
376
3814
11
21
376
3849
—
—
—
7
21
363
3723
11
53
304
3148
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
1.0e+00
—
—
—
—
—
1.6e+00
cases:1.81%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:2.54%
controls:0.50%
7
26
380
3844
—
—
—
—
—
8
16
307
3185
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
8.4e-01
1.6e+00
—
—
—
—
1.9e-01
cases:2.58%
controls:1.14%
cases:2.33%
controls:0.47%
—
—
—
—
—
—
—
—
cases:2.22%
controls:1.84%
10
44
377
3826
9
18
378
3852
—
—
—
—
7
59
308
3142
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
4.7e-03
3.8e-01
7.4e-01
—
8.6e-01
2.0e-01
1.9e-01
cases:33.07%
controls:32.97%
cases:34.11%
controls:26.23%
cases:9.30%
controls:4.65%
—
—
cases:10.62%
controls:4.79%
cases:31.35%
controls:27.19%
cases:51.75%
controls:47.11%
128
1276
259
2594
132
1015
255
2855
36
180
351
3690
—
41
185
345
3676
116
1018
254
2726
163
1508
152
1693
FEV1 --post bronchodilation
20155-8 [3023550]
5.2e-02
—
—
—
—
—
1.6e+00
cases:2.07%
controls:1.96%
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:0.97%
8
76
379
3794
—
—
—
—
—
14
31
301
3170
FVC percent change Respiratory system
69982-7 [42868471]
5.2e-02
—
—
—
—
—
1.6e+00
cases:2.07%
controls:1.96%
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:0.97%
8
76
379
3794
—
—
—
—
—
14
31
301
3170
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
5.2e-02
—
—
—
—
—
1.6e+00
cases:2.07%
controls:1.96%
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:0.97%
8
76
379
3794
—
—
—
—
—
14
31
301
3170
FEV1/FVC --post bronchodilation
69970-2 [42868459]
5.2e-02
—
—
—
—
—
1.6e+00
cases:2.07%
controls:1.96%
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:0.97%
8
76
379
3794
—
—
—
—
—
14
31
301
3170
FEV1 percent change
69983-5 [42868472]
5.2e-02
—
—
—
—
—
1.6e+00
cases:2.07%
controls:1.96%
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:0.97%
8
76
379
3794
—
—
—
—
—
14
31
301
3170
Ultrasound measurement of residual urine
KC1EE [2001305918]
6.9e-01
—
—
—
—
1.4e+00
1.5e+00
cases:2.84%
controls:1.45%
—
—
—
—
—
—
—
—
cases:1.35%
controls:0.35%
cases:4.76%
controls:1.12%
11
56
376
3814
—
—
—
—
5
13
365
3731
15
36
300
3165
Neck symptom/complaint
L01 [2002000626]
3.8e-01
—
—
—
—
1.5e+00
7.2e-01
cases:3.10%
controls:2.14%
—
—
—
—
—
—
—
—
cases:2.97%
controls:0.69%
cases:4.13%
controls:2.06%
12
83
375
3787
—
—
—
—
11
26
359
3718
13
66
302
3135
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
5.2e-01
6.5e-01
9.3e-01
—
1.0e+00
1.5e+00
5.1e-01
cases:9.04%
controls:5.61%
cases:3.88%
controls:2.07%
cases:1.55%
controls:0.62%
—
—
cases:1.81%
controls:0.65%
cases:8.92%
controls:2.19%
cases:9.84%
controls:6.15%
35
217
352
3653
15
80
372
3790
6
24
381
3846
—
7
25
379
3836
33
82
337
3662
31
197
284
3004
Headache
R51.80 [2000503603]
5.0e-01
1.5e+00
—
—
—
1.4e+00
6.8e-01
cases:3.10%
controls:1.91%
cases:2.33%
controls:0.54%
—
—
—
—
—
—
cases:2.16%
controls:0.53%
cases:4.44%
controls:2.31%
12
74
375
3796
9
21
378
3849
—
—
—
8
20
362
3724
14
74
301
3127
Exposure to unspecified factor
X59 [45756412]
3.5e-01
1.4e+00
—
—
—
1.4e+00
3.0e-01
cases:2.84%
controls:2.02%
cases:2.58%
controls:0.67%
—
—
—
—
—
—
cases:2.70%
controls:0.67%
cases:3.17%
controls:2.37%
11
78
376
3792
10
26
377
3844
—
—
—
10
25
360
3719
10
76
305
3125
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
2.4e-01
3.6e-01
—
—
—
9.8e-01
1.4e+00
cases:2.84%
controls:2.25%
cases:1.29%
controls:0.90%
—
—
—
—
—
—
cases:1.62%
controls:0.61%
cases:4.76%
controls:1.22%
11
87
376
3783
5
35
382
3835
—
—
—
6
23
364
3721
15
39
300
3162
FEV1/FVC
19926-5 [3011505]
2.4e-01
3.6e-01
—
—
—
9.8e-01
1.4e+00
cases:2.84%
controls:2.25%
cases:1.29%
controls:0.90%
—
—
—
—
—
—
cases:1.62%
controls:0.61%
cases:4.76%
controls:1.22%
11
87
376
3783
5
35
382
3835
—
—
—
6
23
364
3721
15
39
300
3162
FEV1
20150-9 [3024653]
2.4e-01
3.6e-01
—
—
—
9.8e-01
1.4e+00
cases:2.84%
controls:2.25%
cases:1.29%
controls:0.90%
—
—
—
—
—
—
cases:1.62%
controls:0.61%
cases:4.76%
controls:1.22%
11
87
376
3783
5
35
382
3835
—
—
—
6
23
364
3721
15
39
300
3162
Malaise and fatigue
R53 [45553741]
2.0e-01
1.4e+00
—
—
—
—
5.3e-01
cases:3.88%
controls:3.20%
cases:3.36%
controls:0.85%
—
—
—
—
—
—
—
—
cases:6.98%
controls:4.22%
15
124
372
3746
13
33
374
3837
—
—
—
—
22
135
293
3066
Urgent procedure
ZXD05 [2001311386]
9.6e-02
8.8e-01
—
1.0e+50
—
1.4e+00
1.8e-01
cases:4.39%
controls:4.01%
cases:3.36%
controls:1.42%
—
—
cases:2.07%
controls:0.00%
—
—
cases:3.24%
controls:0.83%
cases:2.86%
controls:2.41%
17
155
370
3715
13
55
374
3815
—
8
0
379
3870
—
12
31
358
3713
9
77
306
3124
terbutaline; inhalant
R03AC03 [21603257]
5.5e-01
1.3e+00
-1.0e+50
—
—
1.0e+00
8.8e-01
cases:4.13%
controls:2.43%
cases:3.36%
controls:0.93%
cases:0.00%
controls:0.21%
—
—
—
—
cases:2.70%
controls:0.99%
cases:4.13%
controls:1.75%
16
94
371
3776
13
36
374
3834
0
8
387
3862
—
—
10
37
360
3707
13
56
302
3145
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
1.3e+00
7.3e-01
—
—
—
7.0e-01
4.2e-01
cases:5.17%
controls:1.50%
cases:2.33%
controls:1.14%
—
—
—
—
—
—
cases:2.43%
controls:1.23%
cases:3.81%
controls:2.53%
20
58
367
3812
9
44
378
3826
—
—
—
9
46
361
3698
12
81
303
3120
Cystoscopy
UKC02 [2001306005]
5.1e-01
—
—
—
-1.0e+50
7.1e-01
1.3e+00
cases:3.36%
controls:2.04%
—
—
—
—
—
—
cases:0.00%
controls:0.13%
cases:1.35%
controls:0.67%
cases:5.40%
controls:1.59%
13
79
374
3791
—
—
—
0
5
386
3856
5
25
365
3719
17
51
298
3150
Essential (primary) hypertension
I10 [45591453]
3.0e-01
4.8e-01
9.1e-01
1.0e+50
1.2e+00
2.5e-01
2.7e-01
cases:24.81%
controls:19.66%
cases:15.25%
controls:10.05%
cases:4.39%
controls:1.81%
cases:4.91%
controls:0.00%
cases:5.96%
controls:1.79%
cases:13.78%
controls:11.08%
cases:31.43%
controls:25.93%
96
761
291
3109
59
389
328
3481
17
70
370
3800
19
0
368
3870
23
69
363
3792
51
415
319
3329
99
830
216
2371
calcium (different salts in combination); oral
A12AA20 [21600872]
2.5e-01
3.8e-01
-3.5e-01
—
4.6e-01
5.7e-01
6.4e-01
cases:15.50%
controls:12.53%
cases:13.18%
controls:9.43%
cases:1.81%
controls:2.56%
—
—
cases:3.89%
controls:2.49%
cases:16.49%
controls:10.07%
cases:24.13%
controls:14.31%
60
485
327
3385
51
365
336
3505
7
99
380
3771
—
15
96
371
3765
61
377
309
3367
76
458
239
2743
Audiology
64 [38004489]
4.1e-01
6.6e-01
—
—
-1.0e+50
8.0e-01
1.2e+00
cases:4.13%
controls:2.79%
cases:2.33%
controls:1.21%
—
—
—
—
cases:0.00%
controls:0.21%
cases:2.97%
controls:1.36%
cases:9.52%
controls:3.06%
16
108
371
3762
9
47
378
3823
—
—
0
8
386
3853
11
51
359
3693
30
98
285
3103
Laboratory test
15220000 [4034850]
3.4e-01
1.2e+00
—
—
-1.0e+50
4.7e-01
1.3e-01
cases:4.13%
controls:2.97%
cases:3.36%
controls:1.03%
—
—
—
—
cases:0.00%
controls:0.31%
cases:2.16%
controls:1.36%
cases:5.40%
controls:4.78%
16
115
371
3755
13
40
374
3830
—
—
0
12
386
3849
8
51
362
3693
17
153
298
3048
pseudoephedrine; oral
R01BA02 [21603210]
1.2e+00
—
—
—
—
-1.0e+50
-9.6e-02
cases:4.13%
controls:1.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:1.90%
controls:2.09%
16
50
371
3820
—
—
—
—
0
23
370
3721
6
67
309
3134
Dorsalgia, unspecified
M54.9 [45538791]
1.2e+00
1.0e+00
—
—
—
—
5.6e-01
cases:4.13%
controls:1.32%
cases:1.29%
controls:0.47%
—
—
—
—
—
—
—
—
cases:2.22%
controls:1.28%
16
51
371
3819
5
18
382
3852
—
—
—
—
7
41
308
3160
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
1.1e+00
—
—
—
—
—
1.1e+00
cases:2.58%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:1.47%
10
35
377
3835
—
—
—
—
—
14
47
301
3154
Normoblasts [#/volume] in Blood
715-3 [3021589]
2.2e-01
2.1e-01
5.4e-01
—
1.1e+00
2.7e-01
3.3e-01
cases:10.34%
controls:8.48%
cases:8.79%
controls:7.24%
cases:2.84%
controls:1.68%
—
—
cases:4.40%
controls:1.48%
cases:9.19%
controls:7.16%
cases:17.78%
controls:13.46%
40
328
347
3542
34
280
353
3590
11
65
376
3805
—
17
57
369
3804
34
268
336
3476
56
431
259
2770
Chest pain, unspecified
R07.4 [45558450]
-1.5e-01
1.1e+00
-1.0e+50
—
-1.0e+50
5.5e-01
2.1e-01
cases:4.39%
controls:5.09%
cases:3.88%
controls:1.32%
cases:0.00%
controls:0.16%
—
—
cases:0.00%
controls:0.16%
cases:2.16%
controls:1.26%
cases:6.35%
controls:5.22%
17
197
370
3673
15
51
372
3819
0
6
387
3864
—
0
6
386
3855
8
47
362
3697
20
167
295
3034
Plastic And Reconstructive Surgery
24 [38004467]
2.0e-01
5.2e-01
—
—
—
7.9e-01
1.1e+00
cases:3.36%
controls:2.76%
cases:1.81%
controls:1.09%
—
—
—
—
—
—
cases:2.43%
controls:1.12%
cases:7.30%
controls:2.56%
13
107
374
3763
7
42
380
3828
—
—
—
9
42
361
3702
23
82
292
3119
pramipexole; oral
N04BC05 [21604477]
1.1e+00
1.0e+00
1.2e+00
—
1.6e+00
9.7e-01
1.0e+00
cases:3.62%
controls:1.24%
cases:2.84%
controls:1.06%
cases:1.29%
controls:0.39%
—
—
cases:1.55%
controls:0.31%
cases:2.43%
controls:0.93%
cases:4.13%
controls:1.50%
14
48
373
3822
11
41
376
3829
5
15
382
3855
—
6
12
380
3849
9
35
361
3709
13
48
302
3153
naproxen; oral, rectal
M01AE02 [21603968]
4.9e-01
1.1e+00
—
—
—
2.9e-01
9.2e-02
cases:13.70%
controls:8.86%
cases:7.24%
controls:2.61%
—
—
—
—
—
—
cases:3.78%
controls:2.86%
cases:7.62%
controls:7.00%
53
343
334
3527
28
101
359
3769
—
—
—
14
107
356
3637
24
224
291
2977
naproxcinod
M01AE18 [40254094]
4.9e-01
1.1e+00
—
—
—
2.9e-01
9.2e-02
cases:13.70%
controls:8.86%
cases:7.24%
controls:2.61%
—
—
—
—
—
—
cases:3.78%
controls:2.86%
cases:7.62%
controls:7.00%
53
343
334
3527
28
101
359
3769
—
—
—
14
107
356
3637
24
224
291
2977
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
3.1e-01
7.8e-01
—
—
—
1.1e+00
3.7e-01
cases:5.43%
controls:4.06%
cases:2.84%
controls:1.32%
—
—
—
—
—
—
cases:3.78%
controls:1.34%
cases:5.08%
controls:3.56%
21
157
366
3713
11
51
376
3819
—
—
—
14
50
356
3694
16
114
299
3087
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
1.6e-01
1.1e+00
—
—
—
-1.3e-01
3.9e-01
cases:5.43%
controls:4.65%
cases:4.13%
controls:1.47%
—
—
—
—
—
—
cases:1.62%
controls:1.84%
cases:6.98%
controls:4.84%
21
180
366
3690
16
57
371
3813
—
—
—
6
69
364
3675
22
155
293
3046
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
3.9e-01
-1.5e-01
—
—
—
1.0e+00
4.7e-01
cases:3.10%
controls:2.12%
cases:1.29%
controls:1.50%
—
—
—
—
—
—
cases:4.86%
controls:1.76%
cases:7.94%
controls:5.12%
12
82
375
3788
5
58
382
3812
—
—
—
18
66
352
3678
25
164
290
3037
Sleep apnoea
G47.3 [45562094]
1.4e-01
2.9e-01
—
1.0e+50
8.8e-01
1.0e+00
6.0e-01
cases:4.65%
controls:4.06%
cases:3.36%
controls:2.53%
—
—
cases:1.29%
controls:0.00%
cases:1.30%
controls:0.54%
cases:6.22%
controls:2.30%
cases:9.84%
controls:5.65%
18
157
369
3713
13
98
374
3772
—
5
0
382
3870
5
21
381
3840
23
86
347
3658
31
181
284
3020
estriol; oral, parenteral, vaginal
G03CA04 [21602518]
—
—
-1.0e+50
—
—
—
1.0e+00
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
cases:4.44%
controls:1.62%
—
—
0
5
387
3865
—
—
—
14
52
301
3149
Osmolality of Urine
2695-5 [3026782]
2.6e-02
-2.4e-01
—
—
1.4e+00
1.0e+00
6.8e-01
cases:4.13%
controls:4.03%
cases:1.55%
controls:1.96%
—
—
—
—
cases:1.30%
controls:0.34%
cases:4.05%
controls:1.52%
cases:7.62%
controls:4.03%
16
156
371
3714
6
76
381
3794
—
—
5
13
381
3848
15
57
355
3687
24
129
291
3072
escitalopram; oral
N06AB10 [21604718]
6.6e-01
7.1e-01
—
—
—
9.9e-01
4.9e-01
cases:5.68%
controls:3.02%
cases:3.10%
controls:1.55%
—
—
—
—
—
—
cases:4.32%
controls:1.66%
cases:5.40%
controls:3.37%
22
117
365
3753
12
60
375
3810
—
—
—
16
62
354
3682
17
108
298
3093
Rheumatology
66 [38004491]
5.2e-01
9.7e-01
—
—
—
6.3e-01
4.5e-01
cases:5.94%
controls:3.62%
cases:4.65%
controls:1.81%
—
—
—
—
—
—
cases:2.97%
controls:1.60%
cases:5.08%
controls:3.31%
23
140
364
3730
18
70
369
3800
—
—
—
11
60
359
3684
16
106
299
3095
piroxicam; ointment
M02AA07 [21604043]
9.4e-01
6.2e-01
—
—
-1.0e+50
—
4.5e-01
cases:8.27%
controls:3.41%
cases:1.81%
controls:0.98%
—
—
—
—
cases:0.00%
controls:0.13%
—
—
cases:5.40%
controls:3.50%
32
132
355
3738
7
38
380
3832
—
—
0
5
386
3856
—
17
112
298
3089
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
9.5e-02
9.4e-01
—
—
1.3e+00
1.5e-01
2.6e-01
cases:5.43%
controls:4.96%
cases:6.46%
controls:2.64%
—
—
—
—
cases:1.30%
controls:0.36%
cases:3.78%
controls:3.26%
cases:12.06%
controls:9.56%
21
192
366
3678
25
102
362
3768
—
—
5
14
381
3847
14
122
356
3622
38
306
277
2895
valsartan; oral
C09CA03 [21601826]
9.4e-01
8.7e-01
—
—
—
8.3e-01
6.7e-01
cases:5.17%
controls:2.09%
cases:4.13%
controls:1.78%
—
—
—
—
—
—
cases:3.78%
controls:1.68%
cases:5.08%
controls:2.66%
20
81
367
3789
16
69
371
3801
—
—
—
14
63
356
3681
16
85
299
3116
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
2.1e-01
9.3e-01
1.9e+00
—
1.6e+00
2.4e-01
3.7e-01
cases:3.88%
controls:3.18%
cases:4.91%
controls:1.99%
cases:1.55%
controls:0.23%
—
—
cases:1.30%
controls:0.26%
cases:3.24%
controls:2.56%
cases:11.75%
controls:8.43%
15
123
372
3747
19
77
368
3793
6
9
381
3861
—
5
10
381
3851
12
96
358
3648
37
270
278
2931
Home Visit
OMOP4822459 [581476]
-9.4e-02
4.4e-01
4.9e-01
—
8.6e-01
9.1e-01
4.0e-01
cases:4.13%
controls:4.52%
cases:4.91%
controls:3.23%
cases:1.81%
controls:1.11%
—
—
cases:2.59%
controls:1.11%
cases:7.84%
controls:3.31%
cases:13.02%
controls:9.15%
16
175
371
3695
19
125
368
3745
7
43
380
3827
—
10
43
376
3818
29
124
341
3620
41
293
274
2908
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
2.0e-01
4.0e-01
—
—
1.2e+00
9.0e-01
4.5e-01
cases:6.20%
controls:5.14%
cases:4.65%
controls:3.18%
—
—
—
—
cases:1.81%
controls:0.54%
cases:7.30%
controls:3.10%
cases:12.06%
controls:8.03%
24
199
363
3671
18
123
369
3747
—
—
7
21
379
3840
27
116
343
3628
38
257
277
2944
trimethoprim; oral, parenteral
J01EA01 [21602931]
9.6e-02
1.3e-01
—
—
—
8.7e-01
-9.0e-02
cases:7.24%
controls:6.61%
cases:2.58%
controls:2.27%
—
—
—
—
—
—
cases:5.68%
controls:2.46%
cases:6.67%
controls:7.25%
28
256
359
3614
10
88
377
3782
—
—
—
21
92
349
3652
21
232
294
2969
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.8e-01
4.7e-01
-1.0e+50
—
—
6.9e-01
8.4e-01
cases:5.68%
controls:4.81%
cases:1.81%
controls:1.14%
cases:0.00%
controls:0.31%
—
—
—
—
cases:2.16%
controls:1.10%
cases:9.84%
controls:4.50%
22
186
365
3684
7
44
380
3826
0
12
387
3858
—
—
8
41
362
3703
31
144
284
3057
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
4.4e-02
8.4e-01
1.3e+00
—
1.1e+00
2.2e-01
1.2e-01
cases:8.53%
controls:8.19%
cases:10.08%
controls:4.63%
cases:2.07%
controls:0.57%
—
—
cases:1.55%
controls:0.54%
cases:6.49%
controls:5.29%
cases:15.87%
controls:14.34%
33
317
354
3553
39
179
348
3691
8
22
379
3848
—
6
21
380
3840
24
198
346
3546
50
459
265
2742
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
8.4e-01
7.7e-01
—
—
-1.0e+50
1.2e-01
4.2e-01
cases:8.79%
controls:4.01%
cases:2.33%
controls:1.09%
—
—
—
—
cases:0.00%
controls:0.16%
cases:1.35%
controls:1.20%
cases:5.71%
controls:3.81%
34
155
353
3715
9
42
378
3828
—
—
0
6
386
3855
5
45
365
3699
18
122
297
3079
citalopram; oral, parenteral
N06AB04 [21604712]
8.0e-01
6.1e-01
—
—
—
5.8e-01
7.9e-01
cases:6.72%
controls:3.13%
cases:3.36%
controls:1.86%
—
—
—
—
—
—
cases:3.51%
controls:2.00%
cases:6.03%
controls:2.84%
26
121
361
3749
13
72
374
3798
—
—
—
13
75
357
3669
19
91
296
3110
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
-1.8e-02
3.0e-01
—
—
—
2.8e-01
6.6e-01
cases:7.49%
controls:7.62%
cases:3.10%
controls:2.33%
—
—
—
—
—
—
cases:2.70%
controls:2.06%
cases:12.06%
controls:6.59%
29
295
358
3575
12
90
375
3780
—
—
—
10
77
360
3667
38
211
277
2990
zopiclone; oral
N05CF01 [21604654]
3.5e-01
6.2e-01
1.0e+00
—
3.5e-01
6.2e-01
6.6e-01
cases:12.92%
controls:9.43%
cases:9.82%
controls:5.56%
cases:3.36%
controls:1.27%
—
—
cases:2.59%
controls:1.84%
cases:10.00%
controls:5.66%
cases:14.92%
controls:8.28%
50
365
337
3505
38
215
349
3655
13
49
374
3821
—
10
71
376
3790
37
212
333
3532
47
265
268
2936
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
6.6e-01
5.5e-01
—
—
—
4.2e-01
-1.1e-01
cases:9.30%
controls:5.04%
cases:2.84%
controls:1.65%
—
—
—
—
—
—
cases:2.70%
controls:1.79%
cases:4.44%
controls:4.94%
36
195
351
3675
11
64
376
3806
—
—
—
10
67
360
3677
14
158
301
3043
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
6.6e-01
9.7e-01
—
—
—
6.9e-01
4.2e-01
cases:11.37%
controls:6.23%
cases:3.88%
controls:1.50%
—
—
—
—
—
—
cases:4.05%
controls:2.08%
cases:8.89%
controls:6.03%
44
241
343
3629
15
58
372
3812
—
—
—
15
78
355
3666
28
193
287
3008
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
6.6e-01
9.7e-01
—
—
—
6.9e-01
4.2e-01
cases:11.37%
controls:6.23%
cases:3.88%
controls:1.50%
—
—
—
—
—
—
cases:4.05%
controls:2.08%
cases:8.89%
controls:6.03%
44
241
343
3629
15
58
372
3812
—
—
—
15
78
355
3666
28
193
287
3008
pseudoephedrine, combinations; oral
R01BA52 [21603213]
5.7e-01
-1.9e-02
—
—
1.3e+00
-1.6e-01
3.4e-01
cases:13.95%
controls:8.42%
cases:2.84%
controls:2.89%
—
—
—
—
cases:1.55%
controls:0.41%
cases:2.97%
controls:3.47%
cases:11.43%
controls:8.43%
54
326
333
3544
11
112
376
3758
—
—
6
16
380
3845
11
130
359
3614
36
270
279
2931
etoricoxib; oral
M01AH05 [21603996]
3.0e-01
3.9e-01
7.6e-01
—
1.3e+00
4.4e-01
4.9e-01
cases:18.09%
controls:14.01%
cases:8.53%
controls:5.92%
cases:1.81%
controls:0.85%
—
—
cases:2.59%
controls:0.75%
cases:9.19%
controls:6.14%
cases:21.90%
controls:14.62%
70
542
317
3328
33
229
354
3641
7
33
380
3837
—
10
29
376
3832
34
230
336
3514
69
468
246
2733
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
1.1e-01
4.9e-01
2.1e-01
—
7.3e-01
2.5e-01
2.2e-01
cases:21.71%
controls:19.84%
cases:17.83%
controls:11.73%
cases:2.33%
controls:1.89%
—
—
cases:2.85%
controls:1.40%
cases:15.14%
controls:12.18%
cases:33.65%
controls:28.90%
84
768
303
3102
69
454
318
3416
9
73
378
3797
—
11
54
375
3807
56
456
314
3288
106
925
209
2276
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
1.1e-01
4.8e-01
6.1e-01
—
7.0e-01
3.5e-01
2.2e-01
cases:28.94%
controls:26.72%
cases:24.55%
controls:16.82%
cases:4.13%
controls:2.30%
—
—
cases:3.89%
controls:1.97%
cases:22.97%
controls:17.33%
cases:43.17%
controls:37.96%
112
1034
275
2836
95
651
292
3219
16
89
371
3781
—
15
76
371
3785
85
649
285
3095
136
1215
179
1986
measles, combinations with mumps, rubella and varicella, live attenuated
J07BD54 [21601346]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
0
6
370
3738
—
Human papilloma virus identified in Specimen
11481-9 [3025130]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
0
9
315
3192
Polymyalgia rheumatica
M35.3 [45533830]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.78%
—
0
8
387
3862
—
—
—
0
10
370
3734
0
25
315
3176
Electrophysiological examination of eye
XCD10 [2001300413]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
387
3858
—
—
—
—
—
—
Lichen sclerosus et atrophicus
L90.0 [45548221]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.69%
—
—
—
—
—
0
11
370
3733
0
22
315
3179
Localized swelling, mass and lump, upper limb
R22.3 [45548956]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
0
6
387
3864
—
—
—
—
—
0
8
315
3193
Vitreous haemorrhage
H43.1 [45543053]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.19%
—
0
6
387
3864
—
—
—
0
9
370
3735
0
6
315
3195
Otalgia
H92.0 [45596177]
9.2e-01
—
—
—
—
—
1.1e+00
cases:1.29%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:1.90%
controls:0.66%
5
20
382
3850
—
—
—
—
—
6
21
309
3180
EKG study
11524-6 [3013512]
3.4e-01
4.5e-02
1.3e+00
—
1.3e+00
3.4e-01
2.2e-01
cases:10.08%
controls:7.36%
cases:4.91%
controls:4.70%
cases:1.55%
controls:0.44%
—
—
cases:2.07%
controls:0.60%
cases:6.22%
controls:4.49%
cases:14.60%
controls:12.06%
39
285
348
3585
19
182
368
3688
6
17
381
3853
—
8
23
378
3838
23
168
347
3576
46
386
269
2815
Striking against or struck by other object(s)
W22 [45756260]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
0
9
315
3192
pravastatin; oral
C10AA03 [21601858]
5.2e-01
4.5e-01
-1.0e+50
—
—
—
—
cases:2.07%
controls:1.24%
cases:1.29%
controls:0.83%
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
8
48
379
3822
5
32
382
3838
0
7
387
3863
—
—
—
—
Pruritus
S02 [2002000967]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
12
315
3189
Heart disease other
K84 [2002000611]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
387
3862
—
—
—
—
—
—
Albumin [Mass/time] in Urine collected for unspecified duration
49002-9 [3050449]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
0
8
387
3862
—
—
—
—
—
Normal-pressure hydrocephalus
G91.2 [45547765]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
387
3863
—
—
—
—
—
—
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
—
—
-1.0e+50
—
—
—
6.5e-01
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
cases:3.81%
controls:2.03%
—
—
0
7
387
3863
—
—
—
12
65
303
3136
Other seborrhoeic dermatitis
L21.8 [45548192]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
0
5
315
3196
dexamethasone and antiinfectives
S03CA01 [21605206]
1.9e-01
—
—
—
—
-1.0e+50
4.1e-01
cases:3.10%
controls:2.58%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:4.13%
controls:2.78%
12
100
375
3770
—
—
—
—
0
19
370
3725
13
89
302
3112
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
1.4e-01
-3.9e-01
—
—
-1.0e+50
-4.7e-01
5.8e-02
cases:13.44%
controls:11.94%
cases:2.33%
controls:3.39%
—
—
—
—
cases:0.00%
controls:0.26%
cases:1.89%
controls:2.99%
cases:12.06%
controls:11.47%
52
462
335
3408
9
131
378
3739
—
—
0
10
386
3851
7
112
363
3632
38
367
277
2834
Other lichen planus
L43.8 [45577038]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.28%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
cases:0.00%
controls:0.19%
cases:0.00%
controls:0.25%
0
11
387
3859
0
8
387
3862
—
—
—
0
7
370
3737
0
8
315
3193
scopolamine
S01FA02 [21605061]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
387
3862
—
—
—
—
—
—
Social worker
Z2446 [2001311559]
1.3e+00
—
—
—
—
—
—
cases:1.29%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
5
14
382
3856
—
—
—
—
—
—
Benign neoplasm nervous system
N75 [2002000780]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:1.62%
controls:0.00%
—
—
—
—
—
—
—
6
0
364
3744
—
Endovenous obliteration of v.saphena parva
PHM77 [2001309539]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
387
3863
—
—
—
—
—
—
Choriogonadotropin [Units/volume] in Urine
25372-4 [3023511]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
387
3864
—
—
—
—
—
—
Myocardial infarction (acute) UNS no detected stenosis of the coronary artery
I21.90 [2000502438]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
387
3865
—
—
—
—
—
—
Open wound of scalp
S01.0 [45592468]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
0
24
387
3846
0
9
387
3861
—
—
—
—
—
Acute pancreatitis, unspecified
K85.9 [45591611]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
387
3863
—
—
—
—
—
—
Initiation and monitoring of IV fluid therapy
SPAT1083 [2001700184]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
18
387
3852
—
—
—
—
—
—
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
J44.1 [45601132]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
0
6
387
3864
—
—
—
0
5
370
3739
—
tolterodine; oral
G04BD07 [21602640]
—
—
—
—
—
-1.0e+50
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:2.22%
controls:0.50%
—
—
—
—
—
0
9
370
3735
7
16
308
3185
acitretin; oral
D05BB02 [21602051]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
387
3864
—
—
—
—
—
—
Spirometry
127783003 [4133840]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.34%
—
—
—
—
—
0
8
370
3736
0
11
315
3190
Elevated level of transaminase and lactic acid dehydrogenase
274774002 [436238]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
7
315
3194
Other change in the oral mucosa
K13.78 [2000502893]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
0
9
387
3861
—
—
—
—
—
0
5
315
3196
bimatoprost
S01EE03 [21603712]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
0
5
387
3865
—
0
6
386
3855
—
—
Chron obstructive pulmonary disease
R95 [2002000960]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
0
7
387
3863
—
—
—
—
—
Desmosome IgG Ab [Titer] in Serum by Immunofluorescence
71368-5 [42870308]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
10
315
3191
Telephone prescription or other care instructions
WZB00 [2001310884]
-9.4e-02
1.8e-01
—
—
—
—
3.2e-01
cases:4.13%
controls:4.52%
cases:1.55%
controls:1.29%
—
—
—
—
—
—
—
—
cases:6.03%
controls:4.47%
16
175
371
3695
6
50
381
3820
—
—
—
—
19
143
296
3058
Day surgery
ZXD20 [2001311388]
8.4e-01
—
—
—
—
—
—
cases:2.58%
controls:1.14%
—
—
—
—
—
—
—
—
—
—
—
—
10
44
377
3826
—
—
—
—
—
—
Repair of incisional hernia using prosthetic material
JAD30 [2001304421]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
387
3863
—
—
—
—
—
—
Surveillance of (intrauterine) contraceptive device
Z30.5 [45547300]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
0
15
387
3855
—
—
—
—
0
7
370
3737
—
Drug-induced neutropenia
D70.82 [2000501376]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
0
5
315
3196
Fracture of tooth, open
S02.51 [45755762]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.90%
controls:0.69%
—
—
—
—
—
—
6
22
309
3179
Internal hemorrhoids with other complications
I84.1 [45562417]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
0
6
315
3195
Recurrent depressive disorder, current episode moderate
F33.1 [45576543]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
11
315
3190
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
1.3e-01
—
-1.0e+50
—
-1.0e+50
—
-3.3e-01
cases:1.55%
controls:1.37%
—
—
cases:0.00%
controls:0.34%
—
—
cases:0.00%
controls:0.26%
—
—
cases:1.90%
controls:2.62%
6
53
381
3817
—
0
13
387
3857
—
0
10
386
3851
—
6
84
309
3117

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
202
1160
2.52
18.01
2.8
2.4
—
—
—
0
0
109
471
2.82
17.30
4.6
6.6
0.59
1.04
mmol/l
0.58
83
401
107
477
2.71
15.85
4.8
6.6
7.41
7.42
ph
0.83
65
275
302
2175
2.65
15.39
5.8
4.8
6.42
6.68
mmol/l
1.76
290
2058
85
346
2.86
14.91
1.4
1.4
—
—
—
0
0
67
244
3.10
14.30
4.5
7.6
24.22
24.45
mmol/l
0.28
67
239
164
934
2.29
13.98
3.9
3.9
93.03
91.33
%
0.40
157
913
272
1991
2.18
11.43
7.3
6.6
1.21
1.21
mmol/l
0.43
235
1718
213
1468
1.98
10.00
2.4
2.2
—
—
—
0
0
184
1211
1.97
9.83
2.7
2.1
202.50
171.48
u/l
0.22
171
1149
26
65
4.21
9.66
2.2
1.1
—
—
—
0
0
232
1683
1.92
8.98
3.5
2.7
—
—
estimate
—
0
0
244
1812
1.91
8.66
6.7
6.0
1.21
1.21
mmol/l
0.76
222
1667
20
34
6.14
7.79
2.3
1.0
—
—
—
0
0
93
552
1.90
6.30
4.2
5.9
105.28
104.13
mmol/l
1.65
93
552
179
1301
1.69
6.01
4.1
3.4
—
—
—
0
0
228
1782
1.66
5.67
15.9
14.4
1.19
1.24
inr
0.93
194
1451
62
335
2.01
5.49
1.9
2.8
66.40
66.56
g/l
0.06
52
306
65
362
1.95
5.28
4.6
6.0
1.18
1.34
mmol/l
0.78
65
356
221
1734
1.62
5.24
5.6
4.5
35.41
35.41
g/l
0.00
212
1630
230
1847
1.59
4.76
7.1
5.9
0.57
0.58
e9/l
0.27
187
1568
34
153
2.34
4.75
1.3
1.9
9.07
10.56
g/l
2.41
26
135
230
1854
1.58
4.63
7.2
5.9
0.04
0.04
e9/l
0.02
187
1575
62
355
1.89
4.62
3.4
3.9
7.36
7.36
ph
0.04
39
251
60
340
1.90
4.62
5.7
7.0
—
—
—
0
0
144
1046
1.59
4.53
5.3
4.3
—
—
—
0
0
234
1906
1.56
4.41
7.4
6.2
0.17
0.19
e9/l
0.86
193
1649
15
45
3.43
4.37
1.4
1.3
—
—
—
0
0
54
302
1.91
4.32
1.8
2.5
—
—
—
0
0
231
1881
1.55
4.32
7.2
6.0
1.72
1.93
e9/l
1.55
192
1651
69
420
1.78
4.23
1.8
1.7
—
—
—
0
0
167
1283
1.52
3.98
3.6
3.5
27.33
109.58
e6/l
0.91
123
991
214
1734
1.51
3.95
2.3
2.2
98.25
96.77
pmol/l
0.14
108
869
153
1162
1.52
3.81
3.5
2.4
54.09
69.62
u/l
1.60
141
1065
60
363
1.77
3.75
2.1
2.2
0.00
0.04
estimate
0.49
11
69
209
1697
1.49
3.75
8.0
6.1
0.67
0.69
%
0.14
195
1578
76
493
1.67
3.70
5.1
4.8
1.07
1.03
mmol/l
0.83
69
452
210
1712
1.48
3.66
2.7
2.6
79.84
80.01
nmol/l
0.03
191
1521
211
1722
1.48
3.65
7.9
6.1
25.27
27.46
%
2.04
197
1626
209
1704
1.48
3.63
7.9
6.0
2.55
2.80
%
0.93
194
1586
90
613
1.61
3.61
3.1
3.3
1.91
2.67
e6/l
0.60
45
291
288
2510
1.54
3.58
6.4
4.9
—
1.61
—
0
5
209
1707
1.48
3.58
7.6
6.0
59.87
57.62
%
1.79
196
1616
153
1177
1.49
3.53
1.7
1.7
20.96
21.73
nmol/l
0.22
126
989
208
1705
1.46
3.45
8.1
6.1
8.78
8.82
%
0.06
193
1592
236
1986
1.47
3.39
7.9
6.3
11.70
11.30
umol/l
0.07
224
1883
98
691
1.56
3.38
1.9
1.7
1107.10
1218.18
nmol/l
0.61
71
510
171
1355
1.46
3.35
4.1
3.7
—
0.80
—
0
5
61
385
1.69
3.28
2.7
2.0
347.46
381.53
nmol/l
0.68
56
361
34
179
1.98
3.26
2.1
2.2
0.00
0.02
estimate
—
9
53
10
24
4.25
3.21
1.9
1.3
180.50
74.99
ng/l
—
10
24
20
85
2.43
3.20
1.8
1.1
67.45
15.11
e6/l
0.44
11
62
180
1452
1.44
3.16
4.3
4.2
51.41
83.24
e6/l
0.77
126
1025
20
87
2.37
3.06
1.9
1.1
1216.31
153.82
e6/l
0.66
13
66
242
2070
1.44
3.03
10.5
9.6
4.14
4.12
e9/l
0.05
203
1800
142
1103
1.45
3.02
3.7
3.4
0.68
0.51
e6/l
0.36
100
812
254
2193
1.44
3.02
4.4
3.2
43.40
46.54
u/l
0.39
240
2034
173
1396
1.43
2.99
3.5
3.5
2.35
2.36
mmol/l
0.55
158
1261
12
37
3.31
2.96
2.2
1.1
—
—
—
0
0
80
556
1.55
2.92
2.5
2.1
—
—
—
0
0
51
318
1.69
2.88
5.2
4.8
0.73
0.90
%
0.25
22
109
68
458
1.59
2.84
2.1
2.9
1.67
1.82
%
0.87
60
413
149
1180
1.42
2.82
3.2
3.1
28.45
29.90
u/l
0.27
136
1110
360
3365
1.79
2.78
24.9
17.1
21.15
24.24
mg/l
1.45
334
2772
126
974
1.43
2.71
3.0
2.2
3.16
3.03
mg/l
0.25
109
836
48
300
1.68
2.69
5.4
5.0
0.00
0.13
%
2.18
19
91
8
19
4.27
2.69
1.9
3.1
631.88
901.11
u/ml
—
8
19
307
2779
1.47
2.60
11.1
8.2
78.87
79.28
u/l
0.06
294
2613
11
37
3.03
2.50
1.4
1.2
—
—
—
0
0
47
299
1.65
2.47
5.2
4.9
0.36
0.53
%
0.48
22
97
100
756
1.43
2.40
3.3
3.0
514.75
519.18
mosm/kgh2o
0.08
87
658
11
39
2.87
2.36
1.8
1.4
15.20
30.71
ng/l
0.98
11
39
69
487
1.51
2.34
1.7
1.4
—
—
—
0
0
6
13
4.67
2.28
7.8
4.0
—
—
—
0
0
58
397
1.54
2.27
3.5
2.6
4.98
6.88
umol/l
1.97
52
350
5
9
5.61
2.22
1.0
1.3
—
—
—
0
0
28
160
1.81
2.16
5.1
3.6
—
—
—
0
0
17
81
2.15
2.16
1.2
1.2
—
—
—
0
0
191
1629
1.33
2.13
12.8
11.7
0.00
0.00
e9/l
0.67
148
1326
74
540
1.46
2.13
1.4
1.2
—
—
—
0
0
47
311
1.58
2.13
6.0
5.4
0.12
0.18
%
0.16
17
88
59
414
1.50
2.06
3.7
3.2
7.38
7.38
ph
0.15
32
238
59
414
1.50
2.06
3.9
3.2
5.71
5.76
kpa
0.17
59
401
21
111
1.94
2.05
1.5
1.4
28.54
27.41
iu/l
0.05
21
92
12
50
2.44
2.04
1.5
1.8
89.31
90.02
%
0.18
12
50
113
899
1.36
1.98
2.9
2.8
4.80
6.30
e6/l
0.65
102
828
43
284
1.58
1.97
2.3
3.0
9.47
10.65
g/l
1.04
37
265
108
854
1.36
1.96
3.1
2.8
2.45
2.46
mmol/l
0.21
99
766
6
16
3.79
1.94
2.7
2.5
—
—
—
0
0
6
16
3.79
1.94
7.8
3.4
—
—
—
0
0
83
633
1.39
1.88
2.9
2.4
11.08
12.80
umol/l
1.33
73
592
150
1255
1.31
1.85
4.6
4.0
7.39
7.40
ph
0.27
116
894
101
802
1.35
1.78
2.0
1.8
471.29
25574721.04
pmol/l
0.72
83
653
68
509
1.41
1.71
1.5
1.3
741.33
562.17
titre
0.22
15
129
18
97
1.90
1.69
1.8
1.8
3.63
4.84
iu/l
—
6
38
189
1648
1.28
1.66
3.7
3.0
141.98
112.78
ug/l
0.62
176
1513
49
350
1.46
1.59
2.4
2.8
66.22
70.77
e9/l
0.52
35
261
7
26
2.72
1.58
1.0
1.2
—
—
—
0
0
224
2003
1.27
1.58
5.1
4.3
0.00
0.01
estimate
0.69
42
382
30
194
1.59
1.53
3.6
3.8
1.02
1.02
ratio
0.29
25
182
49
355
1.43
1.49
2.2
2.3
33.60
30.07
u/l
0.33
42
291
35
238
1.52
1.45
4.5
3.5
7.42
7.42
ph
0.40
30
196
13
66
2.00
1.45
1.8
2.0
42.92
44.61
nmol/l
0.08
13
66
5
16
3.15
1.44
1.6
1.1
126.40
186.63
mmol/24h
—
5
16
6
22
2.75
1.44
1.0
1.2
—
—
—
0
0
111
924
1.28
1.38
1.4
1.3
—
—
—
0
0
48
352
1.41
1.38
2.3
2.1
0.20
0.21
g/l
0.22
40
332
5
17
2.96
1.36
1.2
2.1
—
—
—
0
0
41
294
1.44
1.33
3.8
2.9
5.98
6.11
ph
0.53
25
204
6
24
2.52
1.31
1.0
1.2
145.33
105.62
pmol/l
—
6
24
59
455
1.35
1.26
1.5
1.7
—
—
—
0
0
17
100
1.73
1.25
3.8
3.1
16.50
1.75
index
—
8
53
61
474
1.34
1.25
1.3
1.3
—
—
—
0
0
104
869
1.27
1.25
1.4
1.3
0.89
1.42
u/ml
0.57
22
216
20
124
1.65
1.23
1.6
4.0
1.47
2.63
ratio
0.98
13
67
79
639
1.30
1.22
2.5
2.8
0.84
0.81
mmol/l
1.62
70
600
129
1108
1.24
1.22
5.4
4.4
0.00
0.01
estimate
0.50
42
371
5
19
2.65
1.22
2.8
1.6
44.54
42.61
%
—
5
19
168
1485
1.23
1.21
4.4
4.0
32.53
54.24
ng/l
0.46
133
1120
102
855
1.26
1.19
1.9
1.7
1.02
1.31
mg/l
0.73
83
689
59
460
1.33
1.18
5.7
3.2
3.93
5.59
e9/l
1.11
42
402
218
1983
1.22
1.18
4.9
4.3
0.00
8.46
estimate
0.80
45
414
341
3262
1.33
1.16
7.4
7.0
39.44
39.63
mmol/mol
0.16
314
3037
216
1966
1.22
1.15
4.9
4.3
0.00
0.00
estimate
-0.00
45
405
5
21
2.40
1.09
1.0
1.0
—
—
—
0
0
5
21
2.40
1.09
1.4
4.4
56.80
168.67
nmol/l
—
5
21
10
52
1.95
1.07
1.5
1.3
—
—
—
0
0
7
33
2.14
1.06
1.7
1.9
10.30
9.90
%
—
7
33
16
251
0.62
1.06
1.6
1.4
—
—
—
0
0
56
442
1.31
1.04
1.2
1.3
—
—
—
0
0
5
22
2.29
1.03
1.0
1.4
78.00
73.18
umol/l
—
5
22
337
3233
1.29
1.00
6.7
5.7
1.80
1.96
mu/l
1.91
311
2956
7
35
2.02
1.00
1.0
1.1
—
2.08
—
0
10
7
36
1.96
0.97
1.0
1.0
—
—
—
0
0
56
447
1.29
0.97
3.2
4.2
2.79
18.73
ug/l
1.03
45
374
53
421
1.30
0.95
1.6
1.5
—
—
—
0
0
9
51
1.78
0.95
2.4
3.1
—
—
—
0
0
21
143
1.49
0.92
1.0
1.1
—
—
—
0
0
6
29
2.08
0.89
1.0
1.3
—
—
—
0
0
8
42
1.92
0.89
1.3
1.0
—
—
—
0
0
71
591
1.25
0.89
2.9
2.4
2.26
2.32
g/l
0.31
62
552
55
445
1.27
0.87
2.3
2.1
85.65
129.60
ug/g
1.10
43
344
16
104
1.56
0.86
4.1
4.3
—
—
—
0
0
19
131
1.47
0.80
3.9
2.8
374.88
211.95
mg/l
—
8
44
40
316
1.30
0.77
3.1
2.6
3.29
4.93
ug/l
1.57
35
280
364
3549
1.33
0.77
16.1
12.8
25.69
24.38
u/l
0.34
356
3435
148
1339
1.17
0.77
3.3
3.2
6.26
7.01
mmol/l
1.66
123
1107
66
555
1.23
0.76
3.0
2.4
20.73
22.31
%
0.35
56
525
43
344
1.28
0.76
1.5
1.5
—
—
—
0
0
85
735
1.20
0.75
5.7
5.8
2.62
2.48
ug/l
0.09
76
660
140
1265
1.17
0.73
3.3
3.2
1376.81
1181.07
ng/l
0.25
130
1086
86
746
1.20
0.73
5.0
4.1
122.19
197.12
ng/l
0.31
72
608
86
747
1.19
0.72
1.6
1.4
1.96
2.50
g/l
2.80
46
422
17
118
1.46
0.70
6.2
4.0
26.26
25.44
mmol/l
0.40
17
112
25
187
1.36
0.70
5.2
3.1
24.79
25.14
mmol/l
0.18
25
182
146
1331
1.15
0.68
4.0
4.0
13.04
7.22
mg/mmol
0.46
88
781
7
43
1.64
0.67
1.4
2.1
—
—
—
0
0
82
720
1.18
0.62
1.4
1.3
31.08
38.25
iu/ml
0.22
30
211
126
1146
1.15
0.60
6.6
6.4
—
—
—
0
0
172
1598
1.14
0.59
4.3
3.8
6.31
6.25
ph
0.29
86
879
32
256
1.27
0.59
4.4
2.8
123.16
127.40
g/l
0.68
32
248
15
106
1.43
0.58
2.3
2.4
1.34
1.50
mg/l
0.34
15
93
6
35
1.73
0.58
1.2
1.5
—
—
—
0
0
16
115
1.41
0.57
1.0
1.1
—
—
—
0
0
6
38
1.59
0.54
1.2
1.2
—
—
—
0
0
108
1186
0.88
0.54
3.2
3.6
—
—
—
0
0
29
233
1.26
0.52
1.2
1.3
—
—
—
0
0
17
127
1.35
0.50
1.2
1.4
0.22
0.27
mg/l
—
5
53
16
119
1.36
0.49
1.9
1.3
282.09
307.21
ug/g
0.19
11
70
15
111
1.37
0.47
2.3
1.6
6781.70
20595.69
e6/l
—
10
75
10
68
1.48
0.47
1.0
1.4
—
—
—
0
0
10
68
1.48
0.47
1.0
1.4
—
—
—
0
0
10
68
1.48
0.47
1.0
1.4
—
—
—
0
0
140
1301
1.12
0.47
3.5
3.3
59.66
38.24
mg/l
0.33
89
791
7
49
1.44
0.46
2.1
1.3
—
—
—
0
0
23
183
1.27
0.46
2.5
2.4
—
—
—
0
0
14
103
1.37
0.46
5.8
9.4
—
—
—
0
0
7
50
1.41
0.45
1.1
1.2
—
—
—
0
0
10
69
1.46
0.44
1.0
1.4
—
—
—
0
0
36
304
1.20
0.44
1.1
1.1
—
—
—
0
0
85
770
1.13
0.43
5.4
5.2
—
—
—
0
0
351
3443
1.17
0.43
21.5
15.3
—
—
—
0
0
5
32
1.57
0.42
1.0
1.2
—
—
—
0
0
5
32
1.57
0.42
1.0
1.3
—
—
—
0
0
13
96
1.37
0.42
1.2
1.7
—
—
—
0
0
342
3350
1.16
0.41
6.0
5.6
5.88
5.97
mmol/l
1.01
312
3054
5
33
1.52
0.41
1.6
1.2
—
—
—
0
0
5
34
1.48
0.40
4.6
2.8
—
—
—
0
0
95
1031
0.90
0.39
4.9
3.8
0.00
0.00
estimate
0.50
39
326
50
440
1.16
0.39
3.0
3.3
1.05
0.76
ug/l
0.33
33
291
11
80
1.39
0.39
1.8
1.4
—
—
—
0
0
9
67
1.35
0.38
1.0
1.4
—
—
—
0
0
5
37
1.36
0.37
3.2
2.0
—
—
—
0
0
11
81
1.37
0.36
2.8
3.3
—
—
—
0
0
9
121
0.74
0.35
1.6
1.2
—
—
—
0
0
6
42
1.44
0.35
1.2
1.9
—
—
—
0
0
6
44
1.37
0.34
1.0
1.1
—
—
—
0
0
18
147
1.24
0.31
1.2
1.3
—
—
—
0
0
286
2790
1.09
0.30
5.5
4.5
15.09
14.93
pmol/l
0.47
263
2529
21
176
1.20
0.29
1.8
2.1
3.27
6.68
iu/ml
—
6
47
366
3618
1.16
0.28
37.0
26.3
4.38
4.41
e12/l
0.58
361
3524
366
3618
1.16
0.28
37.2
26.3
6.83
6.68
e9/l
0.56
361
3524
13
104
1.26
0.26
1.8
2.2
55.22
56.93
%
0.11
13
99
149
1553
0.93
0.24
2.0
2.0
1.42
1.32
mmol/l
1.00
129
1285
6
84
0.71
0.24
1.2
1.2
1.50
1.59
g/l
—
6
84
0
10
0.00
0.21
0.0
2.4
—
—
—
0
0
0
10
0.00
0.21
0.0
3.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
26
230
1.14
0.21
3.2
2.3
0.57
0.62
%
0.60
26
230
0
14
0.00
0.20
0.0
4.0
—
51.75
—
0
14
18
207
0.86
0.19
1.9
2.1
—
—
—
0
0
11
92
1.20
0.16
1.1
1.2
—
116.25
—
0
8
26
235
1.11
0.16
3.2
2.3
1.07
1.16
%
0.25
26
235
21
188
1.12
0.15
1.2
1.3
—
—
—
0
0
7
87
0.80
0.14
1.1
1.2
0.82
0.90
g/l
—
7
87
95
915
1.05
0.13
3.3
2.8
330.19
336.94
umol/l
0.25
84
782
85
884
0.95
0.13
5.1
4.4
1.02
1.02
kg/l
0.49
57
588
31
334
0.92
0.13
1.9
1.5
—
—
—
0
0
5
45
1.11
0.10
1.0
1.4
—
—
—
0
0
344
3417
1.05
0.09
6.5
6.4
2.68
2.67
mmol/l
0.06
317
3125
6
54
1.11
0.09
1.0
1.0
—
—
—
0
0
6
57
1.05
0.08
3.8
2.5
—
—
—
0
0
6
58
1.04
0.08
1.2
1.1
—
—
—
0
0
63
652
0.96
0.08
1.4
1.3
2.14
13.11
u/ml
3.19
28
238
27
254
1.07
0.08
1.3
1.3
—
—
—
0
0
16
173
0.92
0.07
1.7
1.7
—
—
—
0
0
15
138
1.09
0.06
1.7
1.3
—
—
—
0
0
11
121
0.91
0.06
2.5
1.8
—
—
—
0
0
273
2746
0.98
0.04
31.2
22.9
330.79
330.78
g/l
0.00
273
2731
10
92
1.09
0.03
2.2
1.2
—
—
—
0
0
336
3350
1.02
0.02
5.7
5.5
4.63
4.65
mmol/l
0.11
311
3075
25
242
1.04
0.02
1.2
1.2
87.33
130.77
u/ml
—
8
90
319
3199
0.99
0.02
4.8
4.5
1.27
1.26
mmol/l
0.07
284
2892
333
3338
0.98
0.01
5.7
5.4
1.50
1.53
mmol/l
0.46
304
3049
30
293
1.03
0.01
5.9
4.4
—
—
—
0
0
18
178
1.01
0.00
1.1
1.2
—
—
—
0
0
148
1478
1.00
0.00
5.3
4.3
0.00
0.03
estimate
1.47
41
335
14
143
0.98
0.00
3.1
2.9
—
—
—
0
0
20
196
1.02
0.00
1.9
1.9
3.29
3.37
mmol/l
0.12
15
156
7
75
0.93
0.00
1.0
1.2
1.09
0.90
nmol/l
—
7
58
8
82
0.98
0.00
3.4
2.5
8.06
8.80
pmol/l
—
8
82
5
56
0.89
-0.00
1.8
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
56
0.89
-0.00
1.8
1.4
—
—
—
0
0
5
52
0.96
-0.00
1.6
2.4
4.20
4.00
mmol/l
—
5
52
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
2.57
—
0
7
5
52
0.96
-0.00
1.6
2.4
106.00
105.94
mmol/l
—
5
52
5
52
0.96
-0.00
1.6
2.4
1.19
1.19
mmol/l
—
5
52
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
56
0.89
-0.00
1.8
1.4
—
—
—
0
0
5
56
0.89
-0.00
1.8
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.8
—
7.24
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
0.02
—
0
6
6
59
1.02
-0.00
3.5
2.1
30.67
31.98
pg
—
6
59
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
68.57
—
0
7
0
9
0.00
-0.00
0.0
2.2
—
150.56
—
0
9

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_BENIGN_MENINGES_SPINAL and mortality.

Females

Parameter HR [95% CI] p-value
CD2_BENIGN_MENINGES_SPINAL 1.32 [1.11, 1.57] 0.002
Birth year 0.995 [0.99, 1.0] 0.287

During the follow-up period (1.1.1998 — 31.12.2019), 262 out of 1097 females with CD2_BENIGN_MENINGES_SPINAL died.

Males

Parameter HR [95% CI] p-value
CD2_BENIGN_MENINGES_SPINAL 1.558 [1.19, 2.03] 0.001
Birth year 0.986 [0.98, 1.0] 0.006

During the follow-up period (1.1.1998 — 31.12.2019), 132 out of 448 males with CD2_BENIGN_MENINGES_SPINAL died.

Mortality risk

Mortality risk for people of age

years, who have CD2_BENIGN_MENINGES_SPINAL.

N-year risk Females Males
1 0.099% 0.339%
5 0.788% 1.945%
10 2.149% 4.442%
15 3.812% 8.205%
20 6.545% 13.631%

Relationships between endpoints

↥

Index endpoint: CD2_BENIGN_MENINGES_SPINAL – Benign neoplasm: Spinal meninges

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data